WO2014138046A1 - Use of agonists of formyl peptide receptor 2 for treating dermatological diseases - Google Patents

Use of agonists of formyl peptide receptor 2 for treating dermatological diseases Download PDF

Info

Publication number
WO2014138046A1
WO2014138046A1 PCT/US2014/020273 US2014020273W WO2014138046A1 WO 2014138046 A1 WO2014138046 A1 WO 2014138046A1 US 2014020273 W US2014020273 W US 2014020273W WO 2014138046 A1 WO2014138046 A1 WO 2014138046A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino
bromophenyl
optionally substituted
carbamoyl
alkyl
Prior art date
Application number
PCT/US2014/020273
Other languages
French (fr)
Inventor
Veena Viswanath
Richard L. Beard
John E. Donello
Edward C. HSIA
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR122017004256A priority Critical patent/BR122017004256A2/en
Priority to EP14713302.9A priority patent/EP2964214A1/en
Priority to CN201480011861.8A priority patent/CN105007908B/en
Priority to KR1020217005968A priority patent/KR20210024691A/en
Priority to BR112015021392-8A priority patent/BR112015021392B1/en
Priority to KR1020157024039A priority patent/KR102223384B1/en
Priority to CA2899804A priority patent/CA2899804A1/en
Priority to RU2015134778A priority patent/RU2696487C2/en
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Priority to JP2015561540A priority patent/JP6196328B2/en
Priority to AU2014226001A priority patent/AU2014226001B2/en
Publication of WO2014138046A1 publication Critical patent/WO2014138046A1/en
Priority to HK16107753.4A priority patent/HK1219661A1/en
Priority to AU2019201538A priority patent/AU2019201538B2/en
Priority to AU2021203183A priority patent/AU2021203183A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/82—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08—Oxygen atoms
    • C07D223/10—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/80—Two oxygen atoms, e.g. hydantoin with hetero atoms or acyl radicals directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/12—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof

Definitions

  • the present invention relates to a method for treating dermal inflammation and dermal diseases by local or systemic delivery, in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2 (FPR2).
  • FPR2 Formyl peptide receptor 2
  • the formyl peptide receptor (FPR) family belongs to the seven transmembrane domain G-protein-coupled receptor (GPCR) family. This family includes 3 members in humans and one member of this family FPR2 (also known as FPRL-1 , ALXA4) is expressed predominantly on inflammatory cells such as monocytes and neutrophils, as well as on T cells and has been shown to play a critical role in leukocyte trafficking during inflammation and human pathology (Chiang N, Serhan CN, Dahlen, S, Drazen JM, Hay DWP, Rovati E, Shimizu T, Yokomizo T, Brink, C.
  • the lipoxin receptor ALX Potent ligand-specific and stereoselective actions in vivo.
  • exogenous and endogenous ligands including serum amyloid A (SAA), chemokine variant sCK38-1 , the neuroprotective peptide humanin, anti-inflammatory eicosanoid lipoxin A4 (LXA4) and glucocorticoid-modulated protein annexin A1 (Chiang N, Serhan CN, Dahlen, S, Drazen JM, Hay DWP, Rovati E, Shimizu T, Yokomizo T, Brink, C.
  • the lipoxin receptor ALX Potent ligand-specific and stereoselective actions in vivo. Pharmacological Reviews 2006; 58: 463-519).
  • FPR2 has been shown to transduce anti-inflammatory effects of arachidonic acid derived Lipoxin A4 (LXA4) in many systems, and has been shown to play a key role in the resolution of
  • FPR2 knockout mice show exaggerated inflammation in disease conditions as expected by the biological role of the receptor (Dufton N, Hannon R, Brancaleone V, Dalli J, Patel HB, Gray M, D'Aquisto F, Buckingham JC, Perretti M, Flower RJ. Antiinflammatory role of the murine formyl-peptide receptor 2: Ligand-specific effects on leukocyte responses and experimental inflammation. Journal of Immunology 2010; 184: 261 1 -2619. Gavins FNE, Hughes EL, Buss NAPS, Holloway PM, Getting SJ, Buckingham JC. Leukocyte recruitment in the brain in sepsis: involvement of the annexinl FPR2/ALX anti-inflammatory system. FASEB 2012; 26: 1 -13).
  • FPR2 Activation of FPR2 by lipoxin A4 or its analogs and by Annexin I protein has been shown to result in anti-inflammatory activity by promoting active resolution of inflammation which involves inhibition of polymorphonuclear neutrophils (PMNs) and eosinophils migration and also stimulate monocyte migration enabling clearance of apoptotic cells from the site of inflammation in a nonphlogistic manner (Gavins FNE, Hughes EL, Buss NAPS, Holloway PM, Getting SJ, Buckingham JC. Leukocyte recruitment in the brain in sepsis: involvement of the annexinl FPR2/ALX anti- inflammatory system.
  • PMNs polymorphonuclear neutrophils
  • eosinophils migration also stimulate monocyte migration enabling clearance of apoptotic cells from the site of inflammation in a nonphlogistic manner
  • Leukocyte recruitment in the brain in sepsis involvement of the annexinl FPR2/ALX anti- inflammatory system.
  • FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin-derived peptide-stimulated phagocytosis.
  • FASEB 2010; 24: 4240-4249 has been shown to inhibit natural killer (NK) cytotoxicity and promote activation of T cells which further contributes to down regulation of tissue damaging inflammatory signals.
  • NK natural killer
  • FPR2 interaction with LXA4 and Annexin has been shown to be beneficial in experimental models of dermal inflammation, angiogenesis, epithelial migration, edema, alopecia and corneal wound healing.
  • FPR2 selectively would also have benefits in skin wound healing given its potent anti-inflammatory and pro-epithelial repair role.
  • some skin diseases have been shown to have an abnormal expression of LL37, a pro- inflammatory cathelicidin which has been shown to be a natural ligand of FPR2.
  • Rosacea Rosacea, LL37 is highly expressed and is believed to play a key role in the pathogenesis (Yamasaki K, Di Nardo A, Bardan A, Murakami M, Ohtake T, Coda A, Dorschner RA, Bonnart C, Descargues P, Hovnanian A, Morhenn VB, Gallo RL. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nature Medicine. 2007;13:975-80).
  • the present invention relates to a method for treating dermal inflammation and dermal diseases by local or systemic delivery, in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2 (FPR2).
  • FPR2 Formyl peptide receptor 2
  • FPR2 agonists will be useful in inhibiting LL-37-mediated inflammatory diseases such as Rosacea.
  • lipoxin A4 and its analogs are hampered by inherent physicochemical properties of the natural poly-olefinic natural product. Therefore, small molecule anti-inflammatory agonists of FPR2 would have a wide variety of therapeutic benefit in inflammatory disorders especially in the skin. FPR2 is widely expressed in human skin and its appendages. FPR2 thus represents an important novel pro-resolutionary molecular target for the development of new therapeutic agents in dermatological diseases with excessive inflammatory responses.
  • the invention pertains to the ability of FPR2 agonists to exhibit dermal antiinflammatory activity with chemical stability and suitable for topical dermal delivery.
  • FPR2 compounds show good potency at the receptor and, importantly, the FPR2 compounds are topically active, and therefore could be administered in many forms, including but not limited to creams, lotions, gels, solutions, sprays, and foams. These compounds may also be administered IV, intramuscularly, intrathecally, subcutaneously, orally or intraperitoneally.
  • rosacea rosacea fulminans, sunburn, psoriasis, menopause-associated hot flashes, flushing and redness associated with hot flashes, erythema associated with hot flashes, hot flashes resulting from orchiectomyatopic dermatitis, treatment of redness and itch from insect bites, photoaging, seborrheic dermatitis, acne, allergic dermatitis, telangiectasia (dilations of previously existing small blood vessels ) of the face, angioectasias, rhinophyma (hypertrophy of the nose with follicular dilation), acnelike skin eruptions (may ooze or crust), burning or stinging sensation, erythema of the skin, cutaneous hyperactivity with dilation of blood vessels of the skin, Lyell's syndrome, Stevens-Johnson syndrome, local itching and discomfort associated with hemorrhoids, hemorrhoids, ery
  • Figure 1 FPR2 agonists show potent wound healing in a mouse model of punch dermal wound.
  • Figure 2 FPR2 agonists block inflammation induced by LL-37 in mouse ears p ⁇ 0.05 vs. vehicle, at all-time points.
  • the present invention relates to a method for treating dermatological inflammation and dermatological diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2 (FPR2).
  • a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2 (FPR2).
  • FPR2 Formyl peptide receptor 2
  • the invention provides the use of at least one agonist of FPR2 for the manufacture of a medicament for the treatment of a dermatological inflammation disease or condition mediated by FPR2 in a mammal
  • the invention provides a method for treating dermatological inflammatory diseases, which comprises administering a pharmaceutical
  • composition comprising a therapeutically effective amount of at least one agonist of FPR2 as disclosed in U.S. patent application S.N.13/668,835, provided that the compounds have binding activity at the FPR2 receptor.
  • the invention provides the use of at least one compound as disclosed in U.S. patent application S.N.13/668,835 for the manufacture of a medicament for the treatment of a dermatological disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor .
  • the invention provides the use of at least one compound as disclosed in U.S. patent application S.N.13/668,835 for treating a dermatological disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor .
  • R 1 is sec-butyl, C 6 -io aryl, -CH 2 - (C 6 -io)aryl, -CH 2 -heterocycle, C -8 cycloalkyl or C 3 -8 cycloalkenyl or heterocycle;
  • R 2 is halogen or methyl
  • R 3 is halogen
  • R 4 is H, methyl or halogen
  • R 5 is OR 6 or NH 2 ;
  • R 6 is H or C 2-4 alkyl.
  • the invention provides a method for treating dermatological inflammatory diseases, which comprises administering a pharmaceutical composition, comprising a therapeutically effective amount of at least one agonist of FPR2 as disclosed in U.S. patent application S.N.13/523,579, provided that the compounds have binding activity at the FPR2 receptor.
  • the invention provides the use of at least one compound as disclosed in U.S. patent application S.N. 13/523,579 for the manufacture of a medicament for the treatment of a dermatological disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor. .
  • the invention provides the use of at least one compound as disclosed in U.S. patent application S.N. 13/523,579 for treating a dermatological disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor.
  • a 1 and b is 0;
  • a 0 and b is 1 ;
  • a is 1 and b is 1 ;
  • R 1 is optionally substituted Ci -8 alkyl, optionally substituted C 3 -8 cycloalkyl, optionally substituted heterocycle, optionally substituted C 3 -8 cycloalkyl, optionally substituted
  • R 2 is optionally substituted Ci -8 alkyl or optionally substituted C 6 -io aryl;
  • R 3 is hydrogen, optionally substituted Ci -8 alkyl, halogen, -COOR 15 , - OR 13 , -
  • NR 11 R 12 , N0 2 optionally substituted heterocycle, optionally substituted C 3-8 cycloalkyl, optionally substituted C 6 -io aryl or optionally substituted C 3-8 cycloalkenyl;
  • R 4 is hydrogen, optionally substituted Ci -8 alkyl, halogen, - COOR 15 , - OR 13 , -
  • NR 11 R 12 , N0 2 optionally substituted heterocycle, optionally substituted C 3-8 cycloalkyl, optionally substituted C 6 -io aryl or optionally substituted C 3-8 cycloalkenyl;
  • R 5 is halogen, -CF 3 or -S(0) n R 14 ;
  • n 0, 1 or 2;
  • R 6 is hydrogen, optionally substituted Ci -8 alkyl, halogen, - COOR 15 , - OR 13 , -
  • NR 11 R 12 , N0 2 optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C 6 -io aryl or optionally substituted C3-8 cycloalkenyl;
  • R 7 is hydrogen, optionally substituted Ci -8 alkyl, halogen, - COOR 15 , - OR 13 , - NR 11 R 12 , N0 2 , optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C 6 -io aryl or optionally substituted C3-8 cycloalkenyl;
  • R 8 is hydrogen, optionally substituted Ci -8 alkyl or optionally substituted C 6 -io aryl;
  • R 9 is hydrogen, optionally substituted Ci -8 alkyl or optionally substituted C 6 -io aryl;
  • R 10 is hydrogen, optionally substituted Ci -8 alkyl or optionally substituted C 6 -io aryl;
  • R 9a is hydrogen, optionally substituted Ci -8 alkyl or optionally substituted C 6 -io aryl;
  • R 10a is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
  • R 11 is hydrogen or optionally substituted C-i-s alkyl
  • R 12 is hydrogen or optionally substituted C-i-s alkyl
  • R 13 is hydrogen or optionally substituted C-i-s alkyl
  • R 14 is hydrogen, CF 3 or optionally substituted Ci -8 alkyl
  • R 15 is hydrogen or optionally substituted Ci -8 alkyl
  • the invention provides a method for treating dermatological inflammatory diseases, which comprises administering a pharmaceutical composition, comprising a therapeutically effective amount of at least one agonist of FPR2 as disclosed in U.S. patent application S.N. 13/673,800, provided that the compounds have binding activity at the FPR2 receptor..
  • the invention provides the use of at least a compound as disclosed in U.S. patent application S.N. 13/673,800 for the manufacture of a medicament for the treatment of a dermatological disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor.
  • the invention provides the use of at least a compound as disclosed in U.S. patent application S.N. 13/673,800 for treating a dermatological disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor.
  • R 1 is halogen, hydrogen, optionally substituted C -8 alkyl, OR 9 , C(0)R 10 , N0 2 ,
  • R ⁇ is halogen, optionally substituted C 14
  • R 3 is hydrogen, optionally substituted C i -8 alkyl, optionally substituted C 3 -8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted C 6-10 aryl, optionally substituted heterocycle, or together with R 5 forms a 10- or 1 1 - membered polycyclic ring which is optionally substituted;
  • R 5 forms a spiro monocyclic or polycyclic, carbocyclic or heterocyclic, saturated or unsaturated 5 to 10 member ring which is optionally substituted;
  • R 5 is hydrogen, optionally substituted C i -8 alkyl, optionally substituted C 3-8 cycloalkyl, optionally substituted C 3-8 cycloalkenyl, optionally substituted C 6 -io aryl, optionally substituted heterocycle, or together with R 4 forms a spiro monocyclic or polycyclic carbocyclic or heterocyclic, saturated or unsaturated 5 to 10 member ring which is optionally substituted or together with R 3 forms a 5 or 6 member ring which is optionally substituted;
  • R 6 is halogen, hydrogen, optionally substituted C i -8 alkyl, OR 9 , C(0)R 10 , N0 2 ,
  • R 7 is halogen, hydrogen, optionally substituted C -8 alkyl, OR 9 , C(0)R 10 , N0 2 ,
  • R 8 is halogen, hydrogen, optionally substituted C i -8 alkyl, OR 9 , C(0)R 10 , N0 2 , NR 13 R 14 , CN, SR 15 or S0 2 R 16 ;
  • R 9 is hydrogen, C(0)(Ci -8 alkyl) or optionally substituted C i -8 alkyl;
  • R 10 is hydrogen, optionally substituted C i -8 alkyl, 0(C i -8 alkyl), NR 11 R 12 or OH;
  • R 11 is hydrogen, optionally substituted C 6 -io aryl or optionally substituted C i -8 alkyl
  • R 12 is hydrogen, optionally substituted C 6 -io aryl or optionally substituted C i -8 alkyl
  • R 13 is hydrogen, optionally substituted C 6 -io aryl or optionally substituted C i -8 alkyl
  • R 14 is hydrogen, optionally substituted C 6 -io aryl, optionally substituted C i -8 alkyl, C(0)(C 1-s alkyl) or S0 2 (C i -8 alkyl);
  • R 15 is hydrogen, optionally substituted C i -8 alkyl or 0(C i -8 alkyl);
  • R 16 is OH, 0(C 1-s alkyl), (C i -8 alkyl) or NR 11 R 12 ;
  • R 17 is hydrogen, optionally substituted C 6 -io aryl or optionally substituted C i -8 alkyl
  • R 18 is hydrogen, C(0)(Ci -8 alkyl), optionally substituted C 6 -io aryl, or optionally substituted C i -8 alkyl
  • R 19 is hydrogen, C(0)(Ci -8 alkyl), optionally substituted C 6 -io aryl or optionally substituted C i -8 alkyl;
  • R 20 is hydrogen, optionally substituted C 6 -io aryl or optionally substituted C i -8 alkyl
  • R 21 is hydrogen, optionally substituted C 6 -io aryl or optionally substituted C i -8 alkyl
  • n is 1 , 2, 3, 4, or 5;
  • n 1 , 2, 3, 4, or 5.
  • the invention provides a method for treating dermatological inflammatory diseases, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of FPR2 as disclosed in U.S. patent application S.N. 13/765,527, provided that the compounds have binding activity at the FPR2 receptor.
  • the invention provides the use of at least one compound as disclosed in U.S. patent application S.N. 13/765,527 for the manufacture of a medicament for the treatment of a dermatological disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor.
  • the invention provides the use of at least one compound as disclosed in U.S. patent application S.N. 13/765,527 for treating a dermatological disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor.
  • R 1 is hydrogen, halogen, substituted or unsubstituted Ci-6 alkyl, substituted or unsubstituted C 2 -6 alkenyl, substituted or unsubstituted C 2 -6 alkynyl, substituted or unsubstituted C 3 -8 cycloalkyl, substituted or unsubstituted C 3 -8 cycloalkenyl substituted or unsubstituted heterocycle or substituted or unsubstituted C 6 -io aryl, or together with R 2 can form an optionally substituted cyclobutyl;
  • R 2 is isopropyl or together with R 3 can form a substituted or unsubstituted 3 to 6 member ring heterocycle or together with R 1 can form an optionally substituted cyclobutyl, cyclopropyl;
  • R 3 is hydrogen, substituted or unsubstituted C-i-6 alkyl, substituted or unsubstituted C 2 -6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted C 3- 8 cycloalkyl, substituted or unsubstituted C 3 -8 cycloalkenyl, substituted or
  • unsubstituted heterocycle substituted or unsubstituted C-6- ⁇ aryl or together with R 2 can form a substituted or unsubstituted 3 to 6 member ring heterocycle.
  • the invention provides a method for treating dermatological inflammatory diseases, which comprises administering a therapeutically effective amount of a pharmaceutical composition, comprising at least one agonist of FPR2 as disclosed in U.S. patent application S.N. 13/409,228, provided that the compounds have binding activity at the FPR2 receptor.
  • the invention provides the use of at least one compound as disclosed in U.S. patent application S.N. 13/409,228 for the manufacture of a medicament for the treatment of a dermatological disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor.
  • the invention provides the use of at least one compound as disclosed in U.S. patent application S.N. 13/409,228 for treating a dermatological disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at th FPR2 receptor.
  • R 1 is H, halogen, -S(0)R 10 , -S(0) 2 R 11 , nitro, cyano, -OCi -6 alkyl, -SCi -6 alkyl, Ci-6 alkyl, -C 2 - 6 alkenyl, - C 2-6 alkynyl, C(0)R 12 , NR 13 R 14 , C 3 - 8 cycloalkyl, C 3 - 8 cycloalkenyl or hydroxyl;
  • R 2 is H, halogen, -S(0)R 10 , -S(0) 2 R 11 , nitro, cyano, -OCi -6 alkyl, -SCi -6 alkyl, Ci-6 alkyl, -C 2-6 alkenyl, - C 2-6 alkynyl, C(0)R 12 , NR 13 R 14 , C 3-8 cycloalkyl, C 3-8 cycloalkenyl or hydroxyl;
  • R 3 is H, halogen, -S(0)R 10 , -S(0) 2 R 11 , nitro, cyano, -OCi -6 alkyl, -SCi -6 alkyl, Ci-6 alkyl, -C 2-6 alkenyl, - C 2-6 alkynyl, C(0)R 12 , NR 13 R 14 , C 3-8 cycloalkyl, C 3-8 cycloalkenyl, C 6 -io aryl or hydroxyl;
  • R 4 is H or C(0)R 12 ;
  • R 5 is H, -OCi-6 alkyl, -SCi -6 alkyl, -Ci -6 alkyl, -C 2-6 alkenyl or - C 2-6 alkynyl;
  • R 6 is H, -OCi-6 alkyl, -SCi -6 alkyl, -Ci -6 alkyl, -C 2-6 alkenyl or - C 2-6 alkynyl;
  • Y is O or S;
  • X is O, NR, or CH 2 ;
  • R 7 is H, halogen, -S(0)R 10 , -S(0) 2 R 11 , nitro, hydroxyl, cyano, -OCi -6 alkyl,
  • R 8 is H, halogen, -S(0)R 10 , -S(0) 2 R 11 , cyano, -OCi -6 alkyl, -SCi -6 alkyl, -Ci -6 alkyl, -C 2-6 alkenyl, - C 2-6 alkynyl, C(0)R 12 , NR 13 R 14 , C 3-8 cycloalkenyl or C 3-8 cycloalkyl;
  • R 9 is H, -S(0) 2 R 11 , -OCi-6 alkyl, -SCi -6 alkyl, -Ci -6 alkyl, -C 2-6 alkenyl, - C 2-6 alkynyl, C(0)R 12 , C 3-8 cycloalkenyl or C 3-8 cycloalkyl ;
  • R 10 is -Ci-6 alkyl, C 3-8 cycloalkyl, or C 3-8 cycloalkenyl ;
  • R 11 is H, hydroxyl, -Ci -6 alkyl, C 3-8 cycloalkyl or C 3-8 cycloalkenyl;
  • R 12 is H, hydroxyl, -Ci -6 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl, NR 13 R 14 or -
  • R 13 is H, -Ci-6 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl S0 2 R 11 or C(0)R 15 ;
  • R 14 is H, -Ci-6 alkyl, C 3-8 cycloalkenyl, aryl, heterocycle or C 3-8 cycloalkyl;
  • R 15 is H, -Ci-6 alkyl, C 3-8 cycloalkenyl or C 3-8 cycloalkyl;
  • R is H, -C-i-6 alkyl, C 3-8 cycloalkenyl or C 3-8 cycloalkyl;
  • R 5 and R 6 are void.
  • the invention provides a method for treating dermatological inflammatory diseases, which comprises administering a pharmaceutical composition, comprising a therapeutically effective amount of at least one agonist of FPR2 as disclosed in U.S. patent application S.N. 13/370,472, provided that the compounds have binding activity at the FPR2 receptor.
  • the invention provides the use of at least one compound as disclosed in U.S. patent application S.N. 13/370,472 for the manufacture of a medicament for the treatment of a dermatological disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor.
  • the invention provides the use of at least one compound as disclosed in U.S. patent application S.N. 13/370,472 for treating a dermatological disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor.
  • A is C 6 -io aryl, Heterocyle, C 3 -8 cycloalkyl or C 3 -8 cycloalkenyl;
  • R 17 is Ci-6 alkyl or
  • B is C6-io aryl, heterocyle, C3-8 cycloalkyl or C3-8 cycloalkenyl;
  • R 1 is H, halogen, -S(0)R 15 , -S(0) 2 R 11 , nitro, cyano, -OCi -6 alkyl, -SCi -6 alkyl, -Ci- 6 alkyl, -C 2 - 6 alkenyl, - C 2-6 alkynyl, C(0)R 12 , NR 13 R 14 , C 3 - 8 cycloalkyl or hydroxyl;
  • R 2 is H, halogen, -S(0)R 15 , -S(0) 2 R 11 , nitro, cyano, -OCi -6 alkyl, -SCi -6 alkyl, -Ci- 6 alkyl, -C 2-6 alkenyl, - C 2-6 alkynyl, C(0)R 12 , NR 13 R 14 , C 3 - 8 cycloalkyl or hydroxyl;
  • R 3 is H, C1-6 alkyl or C3-8 cycloalkyl;
  • R 5a is H, halogen, -S(0)R 15 , -S(0) 2 R 11 , nitro, cyano, -OCi -6 alkyl, -SCi -6 alkyl, -Ci- 6 alkyl, -C 2 - 6 alkenyl, - C 2-6 alkynyl, C(0)R 12 , NR 13 R 14 , C 3 - 8 cycloalkyl or hydroxyl;
  • R 5b is H, halogen, -S(0)R 15 , -S(0) 2 R 11 , nitro, cyano, -OCi -6 alkyl, -SCi -6 alkyl, -Ci- 6 alkyl, -C 2-6 alkenyl, - C 2-6 alkynyl, C(0)R 12 , NR 13 R 14 , C 3 - 8 cycloalkyl or hydroxyl;
  • R 5c is H, halogen, -S(0)R 15 , -
  • R 7 is H, halogen, -S(0)R 15 , -S(0) 2 R 11 , nitro, cyano, -OCi -6 alkyl, -SCi -6 alkyl, -Ci- 6 alkyl, -C 2-6 alkenyl, - C 2-6 alkynyl, C(0)R 12 , NR 13 R 14 , C 3-8 cycloalkyl or hydroxyl;
  • R 8 is H, halogen, -S(0)R 15 , -S(0) 2 R 11 , nitro, cyano, -OCi -6 alkyl, -SCi -6 alkyl, -Ci- 6 alkyl, -C 2-6 alkenyl, - C 2-6 alkynyl, C(0)R 12 , NR 13 R 14 , C 3-8 cycloalkyl or hydroxyl;
  • R 9 is H, halogen, -S(0)R 15 , -S(0) 2 R 11 , nitro, cyano, -OCi -6 alkyl, -SCi -6 alkyl, -Ci- 6 alkyl, -C 2-6 alkenyl, - C 2-6 alkynyl, C(0)R 12 , NR 13 R 14 , C 3-8 cycloalkyl or hydroxyl;
  • R 10 is H, halogen, -S(0)R 15 , -S(0) 2 R 11 , nitro, cyano, -OCi -6 alkyl, -SCi -6 alkyl, -Ci -6 alkyl, -C 2-6 alkenyl, - C 2-6 alkynyl, C(0)R 12 , NR 13 R 14 , C 3-8 cycloalkyl or hydroxyl;
  • X is O or S
  • Y is O or S
  • R 11 is H, hydroxyl, -Ci -6 alkyl, C 3-8 cycloalkyl or NR 13 R 14 ;
  • R 12 is H, hydroxyl, -Ci -6 alkyl, hydroxyl, C 3-8 cycloalkyl, NR 13 R 14 or -OCi -6 alkyl;
  • R 13 is H, -Ci -6 alkyl, C 3-8 cycloalkyl, S0 2 R 11 or C(0)R 16 ;
  • R 14 is H, -C1-6 alkyl or C 3-8 cycloalkyl
  • R 15 is -C1-6 alkyl, or C 3-8 cycloalkyl
  • R 16 is H, -C1-6 alkyl or C 3-8 cycloalkyl
  • n 1-4;
  • n 1-4.
  • the invention provides a method for treating dermatological inflammatory diseases, which comprises administering a pharmaceutical composition, comprising a therapeutically effective amount of at least one agonist of FPR2 as disclosed in U.S. patent application S.N. 13/863,934, provided that the compounds have binding activity at the FPR2 receptor.
  • the invention provides the use of at least one compound as disclosed in U.S. patent application S.N. 13/863,934 for the manufacture of a medicament for the treatment of a dermatological
  • FPR2 disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor.
  • the invention provides the use of at least one compound as disclosed in U.S. patent application S.N. 13/863,934 for treating a dermatological disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor.
  • n 0 or 1 ;
  • R 1 is hydrogen, substituted or unsubstituted Ci -8 alkyl, halogen, -NR 8 R 9 , -NC(0)R 20 , - OR 10 , -OC(0)R 21 -SR 11 , -C(0)R 12 , CN or N0 2 ;
  • R 2 is hydrogen, substituted or unsubstituted Ci -8 alkyl, halogen, - NR 8 R 9 , -NC(0)R 20 , -OR 10 , -OC(0)R 21 ' -SR 11 , -C(0)R 12 , CN or N0 2 ;
  • R 3 is hydrogen, substituted or unsubstituted Ci -8 alkyl, halogen, - NR 8 R 9 , -NC(0)R 20 , -OR 10 , -OC(0)R 21 , -SR 11 , -C(0)R 12 , CN, N0 2 , CF 3 , S(0)R 15 or S(0) 2 R 16 ;
  • R 4 is hydrogen, substituted or unsubstituted Ci -8 alkyl, halogen, - NR 8 R 9 , -NC(0)R 20 , -OR 10 , -OC(0)R 21 , -SR 11 , -C(0)R 12 , CN or N0 2 ;
  • R 5 is hydrogen, substituted or unsubstituted Ci -8 alkyl, halogen, - NR 8 R 9 , -NC(0)R 20 -OR 10 , -OC(0)R 21 , SR 11 , -C(0)R 12 , CN or N0 2 ;
  • R 6 is hydrogen, substituted or unsubstituted C-i -8 alkyl, substituted or unsubstituted heterocycle, substituted or unsubstituted C 3 -8 cycloalkyi, substituted or unsubstituted C-6-10 aryl, substituted or unsubstituted C 3 -8 cycloalkenyl or -CH 2 R 19 ;
  • R 7 is substituted or unsubstituted heterocycle, -SR 11 , -NR 8 R 9 , - N(H)C(0)N(H)S(0) 2 R 19 , -BR 13 R 14 , -S(0)R 15 , -C(0)N(H)(CN), -C(0)N(H)S(0) 2 R 19 , - S(0)(N)(P0 3 H 2 )-, -S(0) 2 R 16 or -P(0)R 17 R 18 ;
  • R 8 is hydrogen, substituted or unsubstituted Ci -8 alkyl substituted or unsubstituted C 3- 8 cycloalkyi, substituted or unsubstituted heterocycle, or substituted or unsubstituted C 6 -io aryl;
  • R 9 is hydrogen, substituted or unsubstituted C-i -8 alkyl substituted or unsubstituted C 3 -8 cycloalkyi, substituted or unsubstituted heterocycle, or substituted or
  • R 10 is hydrogen or substituted or unsubstituted C-i -8 alkyl ;
  • R 11 is hydrogen , substituted or unsubstituted Ci -8 alkyl or -CF 3 ;
  • R 12 is hydrogen, substituted or unsubstituted Ci -8 alkyl, hydroxyl, -OR 24 or -NR 8 R 9 ;
  • R 13 is -OR 22 ;
  • R 14 is -OR 23 ;
  • R 15 is substituted or unsubstituted Ci -8 alkyl
  • R 16 is substituted or unsubstituted Ci- 8 alkyl, -NR 8 R 9 , -NHS(0) 2 R 19 or hydroxyl;
  • R 17 is OR 10 or NR 8 R 9 ;
  • R 18 is OR 10 or NR 8 R 9 ;
  • R 19 is substituted or unsubstituted heterocycle, substituted or unsubstituted C 3-8 cycloalkyi, substituted or unsubstituted C 6 -io aryl or substituted or unsubstituted C 3-8 cycloalkenyl;
  • R 20 is hydrogen, substituted or unsubstituted Ci -8 alkyl substituted or unsubstituted C 3-8 cycloalkyi, substituted or unsubstituted heterocycle, or substituted or
  • R 21 is hydrogen, substituted or unsubstituted Ci -8 alkyl substituted or unsubstituted C 3-8 cycloalkyi, substituted or unsubstituted heterocycle, or substituted or
  • R 22 is hydrogen, substituted or unsubstituted Ci -8 alkyl, or together with R 23 can form a cycle;
  • R 23 is hydrogen, substituted or unsubstituted Ci -8 alkyl, or together with R 22 can form a cycle;
  • R is hydrogen, substituted or unsubstituted d-s alkyl substituted or unsubstituted C 3 -8 cycloalkyi, substituted or unsubstituted heterocycle, or substituted or
  • alkyl refers to saturated, monovalent or divalent hydrocarbon moieties having linear or branched moieties or combinations thereof and containing 1 to 8 carbon atoms.
  • One methylene (-CH 2 -) group, of the alkyl group can be replaced by oxygen, sulfur, sulfoxide, nitrogen, carbonyl, carboxyl, sulfonyl, sulfate, sulfonate, amide, sulfonamide, by a divalent C 3-8 cycloalkyi, by a divalent heterocycle, or by a divalent aryl group.
  • Alkyl groups can have one or more chiral centers.
  • Alkyl groups can be independently substituted by halogen atoms, hydroxyl groups, cycloalkyi groups, amino groups, heterocyclic groups, aryl groups, carboxylic acid groups, phosphonic acid groups, sulphonic acid groups, phosphoric acid groups, nitro groups, amide groups, sulfonamide groups.
  • cycloalkyi refers to a monovalent or divalent group of 3 to 8 carbon atoms derived from a saturated cyclic hydrocarbon.
  • Cycloalkyi groups can be monocyclic or polycyclic. Cycloalkyi can be independently substituted by halogen atoms, sulfonyl C-i-s alkyl groups, sulfoxide C-i-s alkyl groups, sulfonamide groups, nitro groups, cyano groups, -OCi -8 alkyl groups, -SCi -8 alkyl groups, -Ci -8 alkyl groups, -C2-6 alkenyl groups, - C2-6 alkynyl groups, ketone groups, alkylamino groups, amino groups, aryl groups, C3-8 cycloalkyi groups or hydroxyl groups.
  • cycloalkenyl refers to a monovalent or divalent group of 3 to 8 carbon atoms derived from a saturated cycloalkyi having at least one double bond. Cycloalkenyl groups can be monocyclic or polycyclic.
  • Cycloalkenyl groups can be independently substituted by halogen atoms, sulfonyl groups, sulfoxide groups, nitro groups, cyano groups, -OCi -6 alkyl groups, -SCi -6 alkyl groups, -C1-6 alkyl groups, -C2-6 alkenyl groups, - C2-6 alkynyl groups , ketone groups, alkylamino groups, amino groups, aryl groups, C3-8 cycloalkyi groups or hydroxyl groups.
  • halogen refers to an atom of chlorine, bromine, fluorine, iodine.
  • alkenyl refers to a monovalent or divalent hydrocarbon radical having 2 to 6 carbon atoms, derived from a saturated alkyl, having at least one double bond.
  • One methylene (-CH 2 -) group, of the alkenyl can be replaced by oxygen, sulfur, sulfoxide, nitrogen, carbonyl, carboxyl, sulfonyl, sulfate, sulfonate, amide, sulfonamide, by a divalent C 3-8 cycloalkyl, by a divalent heterocycle, or by a divalent aryl group.
  • C 2-6 alkenyl can be in the E or Z configuration.
  • Alkenyl groups can be substituted by alkyl groups, as defined above or by halogen atoms.
  • alkynyl refers to a monovalent or divalent hydrocarbon radical having 2 to 6 carbon atoms, derived from a saturated alkyl, having at least one triple bond.
  • One methylene (-CH 2 -) group, of the alkynyl can be replaced by oxygen, sulfur, sulfoxide, nitrogen, carbonyl, carboxyl, sulfonyl, sulfate, sulfonate, amide, sulfonamide, by a divalent C 3-8 cycloalkyl, by a divalent heterocycle, or by a divalent aryl group.
  • Alkynyl groups can be substituted by alkyl groups, as defined above, or by halogen atoms.
  • heterocycle refers to a 3 to 10 membered ring, which can be aromatic or non-aromatic, saturated or unsaturated, containing at least one heteroatom selected form oxygen, nitrogen, sulfur, or combinations of at least two thereof, interrupting the carbocyclic ring structure.
  • Heterocycles can be monocyclic or polycyclic.
  • Heterocyclic ring moieties can be substituted by halogen atoms, sulfonyl groups, sulfoxide groups, nitro groups, cyano groups, -OC1-6 alkyl groups, -SCi -6 alkyl groups, -Ci -8 alkyl groups, -C 2 -6 alkenyl groups, - C 2 -6 alkynyl groups , ketone groups, alkylamino groups, amino groups, aryl groups, C3-8 cycloalkyl groups or hydroxyl groups.
  • aryl refers to an organic moiety derived from an aromatic hydrocarbon consisting of a ring containing 6 to 10 carbon atoms, by removal of one hydrogen atom.
  • Aryl can be substituted by halogen atoms, sulfonyl C1-6 alkyl groups, sulfoxide C1-6 alkyl groups, sulfonamide groups, carboxcyclic acid groups, Ci -6 alkyl carboxylates (ester) groups, amide groups, nitro groups, cyano groups, -OCi -6 alkyl groups, -SCi -6 alkyl groups, -Ci -6 alkyl groups, -C 2 -6 alkenyl groups, - C 2 -6 alkynyl groups , ketone groups, aldehydes, alkylamino groups, amino groups, aryl groups, C3-8 cycloalkyl groups or hydroxyl groups.
  • Aryls can be monocyclic or polycyclic.
  • hydroxyl as used herein, represents a group of formula "-OH”.
  • carbonyl as used herein, represents a group of formula "-C(O)-".
  • ketone as used herein, represents an organic compound having a carbonyl group linked to a carbon atom such as -(CO)R x wherein R x can be alkyl, aryl, cycloalkyl, cycloalkenyl, heterocycle as defined above.
  • amine as used herein, represents a group of formula "-NR x R y ",wherein R x and R y can be the same or independently H, alkyl, aryl, cycloalkyl, cycloalkenyl, heterocycle as defined above.
  • sulfonyl as used herein, represents a group of formula "-SO 2 " ".
  • carboxylic acid as used herein, represents a group of formula "- C(0)OH”.
  • nitro as used herein, represents a group of formula "-NO 2 ".
  • cyano as used herein, represents a group of formula "-CN”.
  • amide as used herein, represents a group of formula "-C(0)NR x R y " wherein R x and R y can be the same or independently H, alkyl, aryl, cycloalkyl, cycloalkenyl, heterocycle as defined above.
  • R x and R y can be the same or independently H, alkyl, aryl, cycloalkyl, cycloalkenyl, heterocycle as defined above.
  • sulfoxide as used herein, represents a group of formula "-S(O)-".
  • phosphonic acid as used herein, represents a group of formula "- P(0)(OH) 2 ".
  • phosphoric acid as used herein, represents a group of formula "- OP(0)(OH) 2 ".
  • sulphonic acid as used herein, represents a group of formula "- S(0) 2 OH”.
  • N represents a nitrogen atom
  • agonists of FPR2 are compounds selected from Table 1 :
  • JP 63232846 discloses the resolution of N-(p-bromophenylcarbamyl) derivatives ((2S)-2-( ⁇ [(4-bromophenyl)amino]carbonyl ⁇ amino)-3-phenylpropanoic acid, (2S.3S)-
  • agonists of FPR2 are compounds selected from Table 3:
  • the compounds of Table 3 are available from Chemical Libraries such as Chemical Block Ltd.
  • Such methods can be performed, for example, by administering to a subject in need thereof a pharmaceutical composition containing a therapeutically effective amount of at least one compound of the invention.
  • N-formyl peptide receptor like-1 receptor modulators are dermatological inflammation and diseases including, but not limited to, dermal wound healing, hypertrophic scars, keloids, burns, rosacea, atopic dermatitis, acne, psoriasis, seborrheic dermatitis, actinic keratoses, basal cell carcinoma, squamous cell carcinoma, melanoma, viral warts, photoaging, photodamage, melasma, post-inflammatory hyperpigmentation, other disorders of pigmentation, and alopecia (scarring and non-scarring forms).
  • These compounds are useful for the treatment of mammals, including humans, with a range of conditions and diseases that are alleviated by the N-formyl peptide receptor like-1 receptor modulation: dermatological inflammation and diseases including, but not limited to, dermal wound healing, hypertrophic scars, keloids, burns, rosacea, atopic dermatitis, acne, psoriasis, seborrheic dermatitis, actinic keratoses, basal cell carcinoma, squamous cell carcinoma, melanoma, viral warts, photoaging, photodamage, melasma, post-inflammatory hyperpigmentation, other disorders of pigmentation, and alopecia (scarring and non-scarring forms).
  • dermatological inflammation and diseases including, but not limited to, dermal wound healing, hypertrophic scars, keloids, burns, rosacea, atopic dermatitis, acne, psoriasis, seborrheic dermatitis, actinic ker
  • methods for treating disorders associated with modulation of the FPRL-1 receptor can be performed, for example, by administering to a subject in need thereof a therapeutically effective amount of at least one compound of the invention, or any combination thereof, or pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual isomers, enantiomers, and diastereomers thereof.
  • the actual amount of the compound to be administered in any given case will be determined by a physician taking into account the relevant circumstances, such as the severity of the condition, the age and weight of the patient, the patient's general physical condition, the cause of the condition, and the route of administration.
  • the patient will be administered the compound orally in any acceptable form, such as a tablet, liquid, capsule, powder and the like, or other routes may be desirable or necessary, particularly if the patient suffers from nausea.
  • routes may include, without exception, transdermal, parenteral, subcutaneous, intranasal, via an implant stent, intrathecal, intravitreal, topical to the eye, back to the eye, intramuscular, intravenous, and intrarectal modes of delivery.
  • the formulations may be designed to delay release of the active compound over a given period of time, or to carefully control the amount of drug released at a given time during the course of therapy.
  • compositions including at least one compound of the invention in a pharmaceutically acceptable carrier thereof.
  • pharmaceutically acceptable means the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • Pharmaceutical compositions of the present invention can be used in the form of a solid, a solution, an emulsion, a dispersion, a patch, a micelle, a liposome, and the like, wherein the resulting composition contains one or more compounds of the present invention, as an active ingredient, in admixture with an organic or inorganic carrier or excipient suitable for enteral or parenteral applications.
  • Invention compounds may be combined, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, and any other form suitable for use.
  • the carriers which can be used include glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea, medium chain length triglycerides, dextrans, and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form.
  • auxiliary, stabilizing, thickening and coloring agents and perfumes may be used.
  • Invention compounds are included in the pharmaceutical composition in an amount sufficient to produce the desired effect upon the process or disease condition.
  • compositions containing invention compounds may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
  • Compositions intended for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of a sweetening agent such as sucrose, lactose, or saccharin, flavoring agents such as peppermint, oil of wintergreen or cherry, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
  • Tablets containing invention compounds in admixture with non-toxic pharmaceutically acceptable excipients may also be manufactured by known methods.
  • the excipients used may be, for example, (1 ) inert diluents such as calcium carbonate, lactose, calcium phosphate or sodium phosphate; (2) granulating and disintegrating agents such as corn starch, potato starch or alginic acid; (3) binding agents such as gum tragacanth, corn starch, gelatin or acacia, and (4) lubricating agents such as magnesium stearate, stearic acid or talc.
  • the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.
  • formulations for oral use may be in the form of hard gelatin capsules wherein the invention compounds are mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin. They may also be in the form of soft gelatin capsules wherein the invention compounds are mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin.
  • water or an oil medium for example, peanut oil, liquid paraffin or olive oil.
  • compositions containing invention compounds may be in a form suitable for topical use, for example, as oily suspensions, as solutions or suspensions in aqueous liquids or nonaqueous liquids, or as oil-in-water or water-in- oil liquid emulsions.
  • the pharmaceutical compositions may be in the form of a sterile injectable suspension.
  • This suspension may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1 ,3- butanediol.
  • Sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides, fatty acids (including oleic acid), naturally occurring vegetable oils like sesame oil, coconut oil, peanut oil, cottonseed oil, etc., or synthetic fatty vehicles like ethyl oleate or the like. Buffers, preservatives, antioxidants, and the like can be incorporated as required.
  • compositions may be prepared by mixing the invention compounds with a suitable non-irritating excipient, such as cocoa butter, synthetic glyceride esters of polyethylene glycols, which are solid at ordinary temperatures, but liquefy and/or dissolve in the rectal cavity to release the drug.
  • a suitable non-irritating excipient such as cocoa butter, synthetic glyceride esters of polyethylene glycols, which are solid at ordinary temperatures, but liquefy and/or dissolve in the rectal cavity to release the drug.
  • the compounds and pharmaceutical compositions described herein are useful as medicaments in mammals, including humans, for treatment of diseases and/or alleviations of conditions which are responsive to treatment by agonists or functional antagonists of the N-formyl peptide receptor like-1 (FPRL-1 ) receptor.
  • FPRL-1 N-formyl peptide receptor like-1
  • methods for treating a disorder associated with modulation of the N-formyl peptide receptor like-1 (FPRL-1 ) receptor can be performed, for example, by administering to a subject in need thereof a pharmaceutical composition containing a therapeutically effective amount of at least one invention compound.
  • the term "therapeutically effective amount” means the amount of the pharmaceutical composition that will elicit the biological or medical response of a subject in need thereof that is being sought by the researcher, veterinarian, medical doctor or other clinician.
  • the subject in need thereof is a mammal. In some embodiments, the mammal is human.
  • FPR2 agonists would be expected to have significant effects in many different types of dermatological inflammation, but have been exemplified by demonstrating wound healing in a mouse model of punch dermal wound (Figure 2). Antiinflammatory activity in this model has been exemplified with the FPR2 agonists described in Table 4.
  • FLIPR HEK-Ga16 cells stably expressing the human FPR2 receptor was utilized. Cells were plated into 384-well poly-D-lysine coated plates at a density of 18,000 cells per well one day prior to use. The growth media was DMEM medium
  • fetal bovine serum FBS
  • 1 % antibiotic-antimycotic 50 ⁇ g/ml hygromycin
  • 400 ⁇ g/ml geneticin 100 ⁇ g/ml.
  • FBS fetal bovine serum
  • the cells were washed twice with Hank's Balanced Salt Solution supplemented with 20 mM HEPES (HBSS/hepes buffer). The cells were then dye loaded with 2 ⁇ Fluo-4 diluted in the HBSS/Hepes buffer and incubated at 37°C for 40 minutes.
  • Extracellular dye was removed by washing the cell plates four times prior to placing the plates in the FLIPR (Fluorometric Imaging Plate Reader, Molecular Devices). Ligands were diluted in HBSS/Hepes buffer and prepared in 384-well microplates. Data for Ca +2 responses were obtained in relative fluorescence units.
  • Immunohistochemistry Fluorescent immunohistochemistry with antibodies specific to FPR2 was used to determine localization in normal human skin. Anti-FPR2 antibody (Abeam) was used at a dilution of 1 :200 to detect FPR2 protein.
  • Dermal wound healing model Groups of 5 ICR male mice weighing 24-28 g were used. During the study, the tested animals were housed in individual cages. Under hexobarbital (90 mg/kg, i.p.) anesthesia, the shoulder and back region of each animal was shaved. A sharp punch (ID 12 mm) was applied to remove the skin including panniculus carnosus and adherent tissues. The wound area, traced onto clear plastic sheets, was measured by use of an Image - ProPlus (Media
  • mice are euthanized by C0 2 inhalation and ears collected for additional analyses.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to a method for treating dermal inflammation and dermal diseases by local or systemic delivery, in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2 (FPR2).

Description

USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING
DERMATOLOGICAL DISEASES
By: Veena Viswanath, Richard L. Beard, John E. Donello and Edward Hsia
RELATED APPLICATIONS
This application claims the benefit of United States Provisional Patent Application Serial No. 61/773,778 filed March 06, 2013, the disclosure of which is hereby incorporated in its entirety by reference
BACKGROUND OF THE INVENTION
1 . Field of the invention
The present invention relates to a method for treating dermal inflammation and dermal diseases by local or systemic delivery, in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2 (FPR2).
2. Summary of the related art
The formyl peptide receptor (FPR) family belongs to the seven transmembrane domain G-protein-coupled receptor (GPCR) family. This family includes 3 members in humans and one member of this family FPR2 (also known as FPRL-1 , ALXA4) is expressed predominantly on inflammatory cells such as monocytes and neutrophils, as well as on T cells and has been shown to play a critical role in leukocyte trafficking during inflammation and human pathology (Chiang N, Serhan CN, Dahlen, S, Drazen JM, Hay DWP, Rovati E, Shimizu T, Yokomizo T, Brink, C. The lipoxin receptor ALX: Potent ligand-specific and stereoselective actions in vivo.
Pharmacological Reviews 2006; 58: 463-519). FPR2 is an exceptionally
promiscuous receptor that responds to a menagerie of structurally diverse
exogenous and endogenous ligands, including serum amyloid A (SAA), chemokine variant sCK38-1 , the neuroprotective peptide humanin, anti-inflammatory eicosanoid lipoxin A4 (LXA4) and glucocorticoid-modulated protein annexin A1 (Chiang N, Serhan CN, Dahlen, S, Drazen JM, Hay DWP, Rovati E, Shimizu T, Yokomizo T, Brink, C. The lipoxin receptor ALX: Potent ligand-specific and stereoselective actions in vivo. Pharmacological Reviews 2006; 58: 463-519). FPR2 has been shown to transduce anti-inflammatory effects of arachidonic acid derived Lipoxin A4 (LXA4) in many systems, and has been shown to play a key role in the resolution of
inflammation (Dufton N, Perretti M. Therapeutic anti-inflammatory potential of formyl peptide receptor agonists. Pharamcology & Therapeutics 2010; 127: 175-188).
FPR2 knockout mice show exaggerated inflammation in disease conditions as expected by the biological role of the receptor (Dufton N, Hannon R, Brancaleone V, Dalli J, Patel HB, Gray M, D'Aquisto F, Buckingham JC, Perretti M, Flower RJ. Antiinflammatory role of the murine formyl-peptide receptor 2: Ligand-specific effects on leukocyte responses and experimental inflammation. Journal of Immunology 2010; 184: 261 1 -2619. Gavins FNE, Hughes EL, Buss NAPS, Holloway PM, Getting SJ, Buckingham JC. Leukocyte recruitment in the brain in sepsis: involvement of the annexinl FPR2/ALX anti-inflammatory system. FASEB 2012; 26: 1 -13).
Activation of FPR2 by lipoxin A4 or its analogs and by Annexin I protein has been shown to result in anti-inflammatory activity by promoting active resolution of inflammation which involves inhibition of polymorphonuclear neutrophils (PMNs) and eosinophils migration and also stimulate monocyte migration enabling clearance of apoptotic cells from the site of inflammation in a nonphlogistic manner (Gavins FNE, Hughes EL, Buss NAPS, Holloway PM, Getting SJ, Buckingham JC. Leukocyte recruitment in the brain in sepsis: involvement of the annexinl FPR2/ALX anti- inflammatory system. FASEB 2012; 26: 1 -13, Maderna P, Cottell DC, Toivonen T, Dufton N, Dalli J, Perretti M, Godson C. FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin-derived peptide-stimulated phagocytosis. FASEB 2010; 24: 4240-4249). In addition, FPR2 has been shown to inhibit natural killer (NK) cytotoxicity and promote activation of T cells which further contributes to down regulation of tissue damaging inflammatory signals. FPR2 interaction with LXA4 and Annexin has been shown to be beneficial in experimental models of dermal inflammation, angiogenesis, epithelial migration, edema, alopecia and corneal wound healing. (Reville K, Cream JK, Vivers S, Dransfield I, Godson C. Lipoxin A4 redistributes Mysoin 11 A and Cdc42 in macrophages: Implications for phagocytosis of apoptotic leukocytes. Journal of Immunology 2006; 176: 1878-1888; Serhan C. Resolution phase of inflammation: Novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annual reviews of Immunology 2007; 25: 101 -137.; Takano T, Fiore S, Maddox JF, Brady HR, Petasis NA, Serhan CN. Asprin-triggered 15-epi-lipoxin A4 and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors. Journal of
Experimental Medicine 1997; 185: 1693-1704.; Leoni G, Alam A, Neumann PA, Lambeth JD, Cheng G, McCoy J, Hilgarth RS, Kundu K, Murthy N, Kusters D, Reutelingsperger C, Perretti M, Parkos CA, Neish AS, Nusrat A. Annexin A1 , formyl peptide receptor, and NOX1 orchestrate epithelial repair. Journal of Clinical
Investigation. 2013;123:443-54; Leedom A, Sullivan AB, Dong B, Lau D, Gronert K. Endogenous LXA4 circuits are determinants of pathological angiogenesis in response to chronic injury. American Journal of Pathology 2010; 176: 74-84; Tsuruki T, Takahata K, Yoshikawa M. Mechanism of the protective effect of intraperitoneally administered agonists for formyl peptide receptors against chemotherapy-induced alopecia. Biosci Biotechnology Biochemistry. 2007;71 :1 198-202).
Targeting FPR2 selectively would also have benefits in skin wound healing given its potent anti-inflammatory and pro-epithelial repair role. In addition, some skin diseases have been shown to have an abnormal expression of LL37, a pro- inflammatory cathelicidin which has been shown to be a natural ligand of FPR2. In the chronic inflammatory disease Rosacea, LL37 is highly expressed and is believed to play a key role in the pathogenesis (Yamasaki K, Di Nardo A, Bardan A, Murakami M, Ohtake T, Coda A, Dorschner RA, Bonnart C, Descargues P, Hovnanian A, Morhenn VB, Gallo RL. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nature Medicine. 2007;13:975-80).
BRIEF DESCRIPTION OF THE INVENTION
The present invention relates to a method for treating dermal inflammation and dermal diseases by local or systemic delivery, in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2 (FPR2).
Given the anti-inflammatory axis of LXA4-FPR2 we propose that FPR2 agonists will be useful in inhibiting LL-37-mediated inflammatory diseases such as Rosacea.
Pharmaceutical utility of lipoxin A4 and its analogs are hampered by inherent physicochemical properties of the natural poly-olefinic natural product. Therefore, small molecule anti-inflammatory agonists of FPR2 would have a wide variety of therapeutic benefit in inflammatory disorders especially in the skin. FPR2 is widely expressed in human skin and its appendages. FPR2 thus represents an important novel pro-resolutionary molecular target for the development of new therapeutic agents in dermatological diseases with excessive inflammatory responses. The invention pertains to the ability of FPR2 agonists to exhibit dermal antiinflammatory activity with chemical stability and suitable for topical dermal delivery. These FPR2 compounds show good potency at the receptor and, importantly, the FPR2 compounds are topically active, and therefore could be administered in many forms, including but not limited to creams, lotions, gels, solutions, sprays, and foams. These compounds may also be administered IV, intramuscularly, intrathecally, subcutaneously, orally or intraperitoneally. These compounds will be useful for the treatment of dermatological diseases including, but not limited to, rosacea, rosacea fulminans, sunburn, psoriasis, menopause-associated hot flashes, flushing and redness associated with hot flashes, erythema associated with hot flashes, hot flashes resulting from orchiectomyatopic dermatitis, treatment of redness and itch from insect bites, photoaging, seborrheic dermatitis, acne, allergic dermatitis, telangiectasia (dilations of previously existing small blood vessels ) of the face, angioectasias, rhinophyma (hypertrophy of the nose with follicular dilation), acnelike skin eruptions (may ooze or crust), burning or stinging sensation, erythema of the skin, cutaneous hyperactivity with dilation of blood vessels of the skin, Lyell's syndrome, Stevens-Johnson syndrome, local itching and discomfort associated with hemorrhoids, hemorrhoids, erythema multiforme minor, erythema multiforme major, erythema nodosum, eye puffiness, urticaria, pruritis, purpura, varicose veins, contact dermatitis, atopic dermatitis, nummular dermatitis, generalized exfoliative dermatitis, stasis dermatitis, lichen simplex chronicus, perioral dermatitis, pseudofolliculitis barbae, granuloma annulare, actinic keratosis, basal cell carcinoma, squamous cell carcinoma, eczema, dermal wound healing, hypertrophic scars, keloids, burns, rosacea, atopic dermatitis, acne, psoriasis, seborrheic dermatitis, actinic keratoses, basal cell carcinoma, squamous cell carcinoma, melanoma, viral warts, photoaging, photodamage, melasma, post-inflammatory hyperpigmentation, other disorders of pigmentation, and alopecia (scarring and non-scarring forms). The compounds below would be expected to have therapeutic effects in many different types of skin disease, but have been exemplified by demonstrating accelerated wound healing activity in a mouse dermal wound healing model (Figure 1 ), and reduction of LL-37- induced inflammation in mice (Figure 2) and human keratinocytes (Figure 2). Antiinflammatory activity in the LL-37-induced rosacea mouse model has been exemplified with three FPR2 agonists: {[(2S)-2-{[(4-bromo-2- fluorophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}acetic acid,
{[(2S,3S)-2-{[(4-bromophenyl)carbamoyl]amino}-3-methylpentanoyl] amino}acetic acid, {[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}acetic acid. Skin penetration of FPR2 agonists following topical administration has also been demonstrated (Figure 3). BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 FPR2 agonists show potent wound healing in a mouse model of punch dermal wound.
Figure 2 FPR2 agonists block inflammation induced by LL-37 in mouse ears p<0.05 vs. vehicle, at all-time points.
Figure 3. Absorption of FPR2 agonists in an in vitro human skin penetration model. DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to a method for treating dermatological inflammation and dermatological diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2 (FPR2).
In another aspect, the invention provides the use of at least one agonist of FPR2 for the manufacture of a medicament for the treatment of a dermatological inflammation disease or condition mediated by FPR2 in a mammal
In another aspect, the invention provides a method for treating dermatological inflammatory diseases, which comprises administering a pharmaceutical
composition comprising a therapeutically effective amount of at least one agonist of FPR2 as disclosed in U.S. patent application S.N.13/668,835, provided that the compounds have binding activity at the FPR2 receptor.
In another aspect, the invention provides the use of at least one compound as disclosed in U.S. patent application S.N.13/668,835 for the manufacture of a medicament for the treatment of a dermatological disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor .
In another aspect, the invention provides the use of at least one compound as disclosed in U.S. patent application S.N.13/668,835 for treating a dermatological disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor .
The compounds disclosed in U.S. patent application S.N.13/668,835 are represented by Formula I:
Figure imgf000007_0001
Formula I
wherein:
R1 is sec-butyl, C6-io aryl, -CH2- (C6-io)aryl, -CH2-heterocycle, C -8 cycloalkyl or C3-8 cycloalkenyl or heterocycle;
R2 is halogen or methyl;
R3 is halogen;
R4 is H, methyl or halogen;
R5 is OR6 or NH2;
R6 is H or C2-4 alkyl.
In another aspect, the invention provides a method for treating dermatological inflammatory diseases, which comprises administering a pharmaceutical composition, comprising a therapeutically effective amount of at least one agonist of FPR2 as disclosed in U.S. patent application S.N.13/523,579, provided that the compounds have binding activity at the FPR2 receptor.
In another aspect, the invention provides the use of at least one compound as disclosed in U.S. patent application S.N. 13/523,579 for the manufacture of a medicament for the treatment of a dermatological disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor. . In another aspect, the invention provides the use of at least one compound as disclosed in U.S. patent application S.N. 13/523,579 for treating a dermatological disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor.
The compounds disclosed in U.S. patent application S.N. 13/523,579 are represented by Formula II:
Figure imgf000008_0001
Formula II
wherein:
a is 1 and b is 0;
a is 0 and b is 1 ;
a is 1 and b is 1 ;
R1 is optionally substituted Ci-8 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted
C-6-10 aryl, optionally substituted C3-8 cycloalkenyl, -NR11R12 or -OR13;
R2 is optionally substituted Ci-8 alkyl or optionally substituted C6-io aryl;
R3 is hydrogen, optionally substituted Ci-8 alkyl, halogen, -COOR15, - OR13, -
NR11R12, N02, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-io aryl or optionally substituted C3-8 cycloalkenyl;
R4 is hydrogen, optionally substituted Ci-8 alkyl, halogen, - COOR15, - OR13, -
NR11R12, N02, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-io aryl or optionally substituted C3-8 cycloalkenyl;
R5 is halogen, -CF3 or -S(0)nR14;
n is 0, 1 or 2; R6 is hydrogen, optionally substituted Ci-8 alkyl, halogen, - COOR15, - OR13, -
NR11R12, N02, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-io aryl or optionally substituted C3-8 cycloalkenyl;
R7 is hydrogen, optionally substituted Ci-8 alkyl, halogen, - COOR15, - OR13, - NR11R12, N02, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-io aryl or optionally substituted C3-8 cycloalkenyl;
R8 is hydrogen, optionally substituted Ci-8 alkyl or optionally substituted C6-io aryl;
R9 is hydrogen, optionally substituted Ci-8 alkyl or optionally substituted C6-io aryl;
R10 is hydrogen, optionally substituted Ci-8 alkyl or optionally substituted C6-io aryl; R9a is hydrogen, optionally substituted Ci-8 alkyl or optionally substituted C6-io aryl;
R10a is hydrogen, optionally substituted C1-8 alkyl or optionally substituted C6-10 aryl;
R11 is hydrogen or optionally substituted C-i-s alkyl;
R12 is hydrogen or optionally substituted C-i-s alkyl;
R13 is hydrogen or optionally substituted C-i-s alkyl;
R14 is hydrogen, CF3 or optionally substituted Ci-8 alkyl;
R15 is hydrogen or optionally substituted Ci-8 alkyl;
In another aspect, the invention provides a method for treating dermatological inflammatory diseases, which comprises administering a pharmaceutical composition, comprising a therapeutically effective amount of at least one agonist of FPR2 as disclosed in U.S. patent application S.N. 13/673,800, provided that the compounds have binding activity at the FPR2 receptor..
In another aspect, the invention provides the use of at least a compound as disclosed in U.S. patent application S.N. 13/673,800 for the manufacture of a medicament for the treatment of a dermatological disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor..
In another aspect, the invention provides the use of at least a compound as disclosed in U.S. patent application S.N. 13/673,800 for treating a dermatological disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor.
The compounds disclosed in U.S. patent application S.N. 13/673,800 are represented by Formula III:
Figure imgf000010_0001
Formula
R1 is halogen, hydrogen, optionally substituted C -8 alkyl, OR9, C(0)R10, N02,
15
NR13R14, CN, SR lo or S02R )1ID6;.
R^ is halogen, optionally substituted C 14
i-8 alkyl, CF3, ORa, C(0)R10, N02, NR )1133RD 14,
CN, SR15 or S02R 1ID6;.
R3 is hydrogen, optionally substituted C i-8 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted C 6-10 aryl, optionally substituted heterocycle, or together with R5 forms a 10- or 1 1 - membered polycyclic ring which is optionally substituted;
Figure imgf000010_0002
Figure imgf000010_0003
Figure imgf000011_0001
, , , optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted C 6-io aryl, optionally substituted heterocycle, or together with R5 forms a spiro monocyclic or polycyclic, carbocyclic or heterocyclic, saturated or unsaturated 5 to 10 member ring which is optionally substituted;
R5 is hydrogen, optionally substituted C i-8 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted C 6-io aryl, optionally substituted heterocycle, or together with R4 forms a spiro monocyclic or polycyclic carbocyclic or heterocyclic, saturated or unsaturated 5 to 10 member ring which is optionally substituted or together with R3 forms a 5 or 6 member ring which is optionally substituted;
R6 is halogen, hydrogen, optionally substituted C i-8 alkyl, OR9, C(0)R10, N02,
,15
NR13R14, CN, SR15 or S02R16;
R7 is halogen, hydrogen, optionally substituted C -8 alkyl, OR9, C(0)R10, N02,
15
NR13R14, CN, SR '° or S02R )1ID6;. R8 is halogen, hydrogen, optionally substituted C i-8 alkyl, OR9, C(0)R10, N02, NR13R14, CN, SR15 or S02R16;
R9 is hydrogen, C(0)(Ci-8 alkyl) or optionally substituted C i-8 alkyl;
R10 is hydrogen, optionally substituted C i-8 alkyl, 0(C i-8 alkyl), NR11R12 or OH;
R11 is hydrogen, optionally substituted C 6-io aryl or optionally substituted C i-8 alkyl; R12 is hydrogen, optionally substituted C 6-io aryl or optionally substituted C i-8 alkyl; R13 is hydrogen, optionally substituted C 6-io aryl or optionally substituted C i-8 alkyl; R14 is hydrogen, optionally substituted C 6-io aryl, optionally substituted C i-8 alkyl, C(0)(C 1-s alkyl) or S02(C i-8 alkyl);
R15 is hydrogen, optionally substituted C i-8 alkyl or 0(C i-8 alkyl);
R16 is OH, 0(C 1-s alkyl), (C i-8 alkyl) or NR11R12;
R17 is hydrogen, optionally substituted C 6-io aryl or optionally substituted C i-8 alkyl; R18 is hydrogen, C(0)(Ci-8 alkyl), optionally substituted C 6-io aryl, or optionally substituted C i-8 alkyl;
R19 is hydrogen, C(0)(Ci-8 alkyl), optionally substituted C 6-io aryl or optionally substituted C i-8 alkyl;
R20 is hydrogen, optionally substituted C 6-io aryl or optionally substituted C i-8 alkyl; R21 is hydrogen, optionally substituted C 6-io aryl or optionally substituted C i-8 alkyl; n is 1 , 2, 3, 4, or 5;
m is 1 , 2, 3, 4, or 5.
In another aspect, the invention provides a method for treating dermatological inflammatory diseases, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of FPR2 as disclosed in U.S. patent application S.N. 13/765,527, provided that the compounds have binding activity at the FPR2 receptor.
In another aspect, the invention provides the use of at least one compound as disclosed in U.S. patent application S.N. 13/765,527 for the manufacture of a medicament for the treatment of a dermatological disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor.
In another aspect, the invention provides the use of at least one compound as disclosed in U.S. patent application S.N. 13/765,527 for treating a dermatological disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor.
The compounds disclosed in U.S. patent application S.N. 13/765,527 are represented by Formu
Figure imgf000013_0001
Formula IV
wherein:
R1 is hydrogen, halogen, substituted or unsubstituted Ci-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl substituted or unsubstituted heterocycle or substituted or unsubstituted C6-io aryl, or together with R2 can form an optionally substituted cyclobutyl;
R2 is isopropyl or together with R3 can form a substituted or unsubstituted 3 to 6 member ring heterocycle or together with R1 can form an optionally substituted cyclobutyl, cyclopropyl; and
R3 is hydrogen, substituted or unsubstituted C-i-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted C3- 8 cycloalkyl, substituted or unsubstituted C3-8 cycloalkenyl, substituted or
unsubstituted heterocycle, substituted or unsubstituted C-6-ιο aryl or together with R2 can form a substituted or unsubstituted 3 to 6 member ring heterocycle.
In another aspect, the invention provides a method for treating dermatological inflammatory diseases, which comprises administering a therapeutically effective amount of a pharmaceutical composition, comprising at least one agonist of FPR2 as disclosed in U.S. patent application S.N. 13/409,228, provided that the compounds have binding activity at the FPR2 receptor.
In another aspect, the invention provides the use of at least one compound as disclosed in U.S. patent application S.N. 13/409,228 for the manufacture of a medicament for the treatment of a dermatological disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor.
In another aspect, the invention provides the use of at least one compound as disclosed in U.S. patent application S.N. 13/409,228 for treating a dermatological disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at th FPR2 receptor.
Figure imgf000014_0001
wherein:
m
is a single bond or a double bond;
"is a single bond or a double bond;
R1 is H, halogen, -S(0)R10, -S(0)2R11, nitro, cyano, -OCi-6 alkyl, -SCi-6 alkyl, Ci-6 alkyl, -C2-6 alkenyl, - C2-6 alkynyl, C(0)R12, NR13R14, C3-8 cycloalkyl, C3-8 cycloalkenyl or hydroxyl;
R2 is H, halogen, -S(0)R10, -S(0)2R11, nitro, cyano, -OCi-6 alkyl, -SCi-6 alkyl, Ci-6 alkyl, -C2-6 alkenyl, - C2-6 alkynyl, C(0)R12, NR13R14, C3-8 cycloalkyl, C3-8 cycloalkenyl or hydroxyl;
R3 is H, halogen, -S(0)R10, -S(0)2R11, nitro, cyano, -OCi-6 alkyl, -SCi-6 alkyl, Ci-6 alkyl, -C2-6 alkenyl, - C2-6 alkynyl, C(0)R12, NR13R14, C3-8 cycloalkyl, C3-8 cycloalkenyl, C6-io aryl or hydroxyl;
R4 is H or C(0)R12;
R5 is H, -OCi-6 alkyl, -SCi-6 alkyl, -Ci-6 alkyl, -C2-6 alkenyl or - C2-6 alkynyl; R6 is H, -OCi-6 alkyl, -SCi-6 alkyl, -Ci-6 alkyl, -C2-6 alkenyl or - C2-6 alkynyl; Y is O or S;
X is O, NR, or CH2;
Figure imgf000014_0002
cycloalkenyl or H; Rb is halogen;
Figure imgf000015_0001
R7 is H, halogen, -S(0)R10, -S(0)2R11 , nitro, hydroxyl, cyano, -OCi-6 alkyl,
SCi-6 alIkkyyll,, --CC1i--66 aallkkyyll,, --CC22--66 aallkkeenyl, - C2-6 alkynyl, C(0)R , NR R , C3-8
cycloalkenyl or C3-8 cycloalkyl;
R8 is H, halogen, -S(0)R10, -S(0)2R11 , cyano, -OCi-6 alkyl, -SCi-6 alkyl, -Ci-6 alkyl, -C2-6 alkenyl, - C2-6 alkynyl, C(0)R12, NR13R14, C3-8 cycloalkenyl or C3-8 cycloalkyl;
R9 is H, -S(0)2R11, -OCi-6 alkyl, -SCi-6 alkyl, -Ci-6 alkyl, -C2-6 alkenyl, - C2-6 alkynyl, C(0)R12, C3-8 cycloalkenyl or C3-8 cycloalkyl ;
R10 is -Ci-6 alkyl, C3-8 cycloalkyl, or C3-8 cycloalkenyl ;
R11 is H, hydroxyl, -Ci-6 alkyl, C3-8 cycloalkyl or C3-8 cycloalkenyl;
R12 is H, hydroxyl, -Ci-6 alkyl, C3-8 cycloalkyl, C3-8 cycloalkenyl, NR13R14 or -
OCi-6 alkyl;
R13 is H, -Ci-6 alkyl, C3-8 cycloalkyl, C3-8 cycloalkenyl S02R11 or C(0)R15; R14 is H, -Ci-6 alkyl, C3-8 cycloalkenyl, aryl, heterocycle or C3-8 cycloalkyl;
R15 is H, -Ci-6 alkyl, C3-8 cycloalkenyl or C3-8 cycloalkyl; and
R is H, -C-i-6 alkyl, C3-8 cycloalkenyl or C3-8 cycloalkyl;
with the proviso
when " " is a double bond then R5 and R6 are void.
In another aspect, the invention provides a method for treating dermatological inflammatory diseases, which comprises administering a pharmaceutical composition, comprising a therapeutically effective amount of at least one agonist of FPR2 as disclosed in U.S. patent application S.N. 13/370,472, provided that the compounds have binding activity at the FPR2 receptor. In another aspect, the invention provides the use of at least one compound as disclosed in U.S. patent application S.N. 13/370,472 for the manufacture of a medicament for the treatment of a dermatological disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor.
In another aspect, the invention provides the use of at least one compound as disclosed in U.S. patent application S.N. 13/370,472 for treating a dermatological disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor.
The compounds as disclosed in U.S. patent application S.N. 13/370,472 are represented by Formula VI:
Figure imgf000016_0001
Formula VI wherein:
A is C6-io aryl, Heterocyle, C3-8 cycloalkyl or C3-8 cycloalkenyl;
R17 is Ci-6 alkyl or
Figure imgf000016_0002
B is C6-io aryl, heterocyle, C3-8 cycloalkyl or C3-8 cycloalkenyl;
R1 is H, halogen, -S(0)R15, -S(0)2R11, nitro, cyano, -OCi-6 alkyl, -SCi-6 alkyl, -Ci-6 alkyl, -C2-6 alkenyl, - C2-6 alkynyl, C(0)R12, NR13R14, C3-8 cycloalkyl or hydroxyl; R2 is H, halogen, -S(0)R15, -S(0)2R11, nitro, cyano, -OCi-6 alkyl, -SCi-6 alkyl, -Ci-6 alkyl, -C2-6 alkenyl, - C2-6 alkynyl, C(0)R12, NR13R14, C3-8 cycloalkyl or hydroxyl; R3 is H, C1-6 alkyl or C3-8 cycloalkyl; R4 is H, Ci-6 alkyl or C3-8 cycloalkyl;
R5a is H, halogen, -S(0)R15, -S(0)2R11, nitro, cyano, -OCi-6 alkyl, -SCi-6 alkyl, -Ci-6 alkyl, -C2-6 alkenyl, - C2-6 alkynyl, C(0)R12, NR13R14, C3-8 cycloalkyl or hydroxyl; R5b is H, halogen, -S(0)R15, -S(0)2R11, nitro, cyano, -OCi-6 alkyl, -SCi-6 alkyl, -Ci-6 alkyl, -C2-6 alkenyl, - C2-6 alkynyl, C(0)R12, NR13R14, C3-8 cycloalkyl or hydroxyl; R5c is H, halogen, -S(0)R15, -S(0)2R11, nitro, cyano, -OCi-6 alkyl, -SCi-6 alkyl, -Ci-6 alkyl, -C2-6 alkenyl, - C2-6 alkynyl, C(0)R12, NR13R14, C3-8 cycloalkyl or hydroxyl; R5d is H, halogen, -S(0)R15, -S(0)2R11, nitro, cyano, -OCi-6 alkyl, -SCi-6 alkyl, -Ci-6 alkyl, -C2-6 alkenyl, - C2-6 alkynyl, C(0)R12, NR13R14, C3-8 cycloalkyl or hydroxyl; R6 is H, -S(0)2R11, -Ci-6 alkyl, -(CH2)n NR13R14, -(CH2)m heterocycle , C(0)R12, NR13R14, C3-8 cycloalkyl, C-6-10 aryl, or heterocycle;
R7 is H, halogen, -S(0)R15, -S(0)2R11, nitro, cyano, -OCi-6 alkyl, -SCi-6 alkyl, -Ci-6 alkyl, -C2-6 alkenyl, - C2-6 alkynyl, C(0)R12, NR13R14, C3-8 cycloalkyl or hydroxyl;
R8 is H, halogen, -S(0)R15, -S(0)2R11, nitro, cyano, -OCi-6 alkyl, -SCi-6 alkyl, -Ci-6 alkyl, -C2-6 alkenyl, - C2-6 alkynyl, C(0)R12, NR13R14, C3-8 cycloalkyl or hydroxyl;
R9 is H, halogen, -S(0)R15, -S(0)2R11, nitro, cyano, -OCi-6 alkyl, -SCi-6 alkyl, -Ci-6 alkyl, -C2-6 alkenyl, - C2-6 alkynyl, C(0)R12, NR13R14, C3-8 cycloalkyl or hydroxyl;
R10 is H, halogen, -S(0)R15, -S(0)2R11, nitro, cyano, -OCi-6 alkyl, -SCi-6 alkyl, -Ci-6 alkyl, -C2-6 alkenyl, - C2-6 alkynyl, C(0)R12, NR13R14, C3-8 cycloalkyl or hydroxyl;
X is O or S;
Y is O or S;
R11 is H, hydroxyl, -Ci-6 alkyl, C3-8 cycloalkyl or NR13R14;
R12 is H, hydroxyl, -Ci-6 alkyl, hydroxyl, C3-8 cycloalkyl, NR13R14 or -OCi-6 alkyl;
R13 is H, -Ci-6 alkyl, C3-8 cycloalkyl, S02R11 or C(0)R16;
R14 is H, -C1-6 alkyl or C3-8 cycloalkyl;
R15 is -C1-6 alkyl, or C3-8 cycloalkyl;
R16 is H, -C1-6 alkyl or C3-8 cycloalkyl;
n is 1-4; and
m is 1-4.
In another aspect, the invention provides a method for treating dermatological inflammatory diseases, which comprises administering a pharmaceutical composition, comprising a therapeutically effective amount of at least one agonist of FPR2 as disclosed in U.S. patent application S.N. 13/863,934, provided that the compounds have binding activity at the FPR2 receptor.
In another aspect, the invention provides the use of at least one compound as disclosed in U.S. patent application S.N. 13/863,934 for the manufacture of a medicament for the treatment of a dermatological
disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor.
In another aspect, the invention provides the use of at least one compound as disclosed in U.S. patent application S.N. 13/863,934 for treating a dermatological disease or condition mediated by FPR2 in a mammal, provided that the compounds have binding activity at the FPR2 receptor.
The compounds as disclosed in U.S. patent application S.N. 13/863,934 are represented by Formula VII:
Figure imgf000018_0001
Formula VII
wherein:
n is 0 or 1 ;
R1 is hydrogen, substituted or unsubstituted Ci-8 alkyl, halogen, -NR8R9, -NC(0)R20, - OR10, -OC(0)R21 -SR11 , -C(0)R12, CN or N02;
R2 is hydrogen, substituted or unsubstituted Ci-8 alkyl, halogen, - NR8R9, -NC(0)R20 , -OR10, -OC(0)R21 ' -SR 11, -C(0)R12, CN or N02;
R3 is hydrogen, substituted or unsubstituted Ci-8 alkyl, halogen, - NR8R9, -NC(0)R20 , -OR10, -OC(0)R21 , -SR11 , -C(0)R12, CN, N02, CF3, S(0)R15 or S(0)2R16;
R4 is hydrogen, substituted or unsubstituted Ci-8 alkyl, halogen, - NR8R9, -NC(0)R20 , -OR10, -OC(0)R21 , -SR11 , -C(0)R12, CN or N02;
R5 is hydrogen, substituted or unsubstituted Ci-8 alkyl, halogen, - NR8R9, -NC(0)R20 -OR10, -OC(0)R21 , SR11 , -C(0)R12, CN or N02; R6 is hydrogen, substituted or unsubstituted C-i-8 alkyl, substituted or unsubstituted heterocycle, substituted or unsubstituted C3-8 cycloalkyi, substituted or unsubstituted C-6-10 aryl, substituted or unsubstituted C3-8 cycloalkenyl or -CH2R19;
R7 is substituted or unsubstituted heterocycle, -SR11, -NR8R9 , - N(H)C(0)N(H)S(0)2R19, -BR13R14, -S(0)R15, -C(0)N(H)(CN), -C(0)N(H)S(0)2R19, - S(0)(N)(P03H2)-, -S(0)2R16 or -P(0)R17R18;
R8 is hydrogen, substituted or unsubstituted Ci-8 alkyl substituted or unsubstituted C3- 8 cycloalkyi, substituted or unsubstituted heterocycle, or substituted or unsubstituted C6-io aryl;
R9 is hydrogen, substituted or unsubstituted C-i-8 alkyl substituted or unsubstituted C3-8 cycloalkyi, substituted or unsubstituted heterocycle, or substituted or
unsubstituted C6-io aryl;
R10 is hydrogen or substituted or unsubstituted C-i-8 alkyl ;
R11 is hydrogen , substituted or unsubstituted Ci-8 alkyl or -CF3;
R12 is hydrogen, substituted or unsubstituted Ci-8 alkyl, hydroxyl, -OR24 or -NR8R9; R13 is -OR22;
R14 is -OR23;
R15 is substituted or unsubstituted Ci-8 alkyl;
R16 is substituted or unsubstituted Ci-8 alkyl, -NR8R9 , -NHS(0)2R19 or hydroxyl;
R17 is OR10 or NR8R9;
R18 is OR10 or NR8R9;
R19 is substituted or unsubstituted heterocycle, substituted or unsubstituted C3-8 cycloalkyi, substituted or unsubstituted C6-io aryl or substituted or unsubstituted C3-8 cycloalkenyl;
R20 is hydrogen, substituted or unsubstituted Ci-8 alkyl substituted or unsubstituted C3-8 cycloalkyi, substituted or unsubstituted heterocycle, or substituted or
unsubstituted C6-io aryl;
R21 is hydrogen, substituted or unsubstituted Ci-8 alkyl substituted or unsubstituted C3-8 cycloalkyi, substituted or unsubstituted heterocycle, or substituted or
unsubstituted C6-io aryl;
R22 is hydrogen, substituted or unsubstituted Ci-8 alkyl, or together with R23 can form a cycle;
R23 is hydrogen, substituted or unsubstituted Ci-8 alkyl, or together with R22 can form a cycle; R is hydrogen, substituted or unsubstituted d-s alkyl substituted or unsubstituted C3-8 cycloalkyi, substituted or unsubstituted heterocycle, or substituted or
unsubstituted C6-io aryl.
The term "alkyl", as used herein, refers to saturated, monovalent or divalent hydrocarbon moieties having linear or branched moieties or combinations thereof and containing 1 to 8 carbon atoms. One methylene (-CH2-) group, of the alkyl group can be replaced by oxygen, sulfur, sulfoxide, nitrogen, carbonyl, carboxyl, sulfonyl, sulfate, sulfonate, amide, sulfonamide, by a divalent C 3-8 cycloalkyi, by a divalent heterocycle, or by a divalent aryl group. Alkyl groups can have one or more chiral centers. Alkyl groups can be independently substituted by halogen atoms, hydroxyl groups, cycloalkyi groups, amino groups, heterocyclic groups, aryl groups, carboxylic acid groups, phosphonic acid groups, sulphonic acid groups, phosphoric acid groups, nitro groups, amide groups, sulfonamide groups.
The term "cycloalkyi", as used herein, refers to a monovalent or divalent group of 3 to 8 carbon atoms derived from a saturated cyclic hydrocarbon. Cycloalkyi groups can be monocyclic or polycyclic. Cycloalkyi can be independently substituted by halogen atoms, sulfonyl C-i-s alkyl groups, sulfoxide C-i-s alkyl groups, sulfonamide groups, nitro groups, cyano groups, -OCi-8 alkyl groups, -SCi-8 alkyl groups, -Ci-8 alkyl groups, -C2-6 alkenyl groups, - C2-6 alkynyl groups, ketone groups, alkylamino groups, amino groups, aryl groups, C3-8 cycloalkyi groups or hydroxyl groups..
The term "cycloalkenyl", as used herein, refers to a monovalent or divalent group of 3 to 8 carbon atoms derived from a saturated cycloalkyi having at least one double bond. Cycloalkenyl groups can be monocyclic or polycyclic. Cycloalkenyl groups can be independently substituted by halogen atoms, sulfonyl groups, sulfoxide groups, nitro groups, cyano groups, -OCi-6 alkyl groups, -SCi-6 alkyl groups, -C1-6 alkyl groups, -C2-6 alkenyl groups, - C2-6 alkynyl groups , ketone groups, alkylamino groups, amino groups, aryl groups, C3-8 cycloalkyi groups or hydroxyl groups.
The term "halogen", as used herein, refers to an atom of chlorine, bromine, fluorine, iodine.
The term "alkenyl", as used herein, refers to a monovalent or divalent hydrocarbon radical having 2 to 6 carbon atoms, derived from a saturated alkyl, having at least one double bond. One methylene (-CH2-) group, of the alkenyl can be replaced by oxygen, sulfur, sulfoxide, nitrogen, carbonyl, carboxyl, sulfonyl, sulfate, sulfonate, amide, sulfonamide, by a divalent C 3-8 cycloalkyl, by a divalent heterocycle, or by a divalent aryl group. C 2-6 alkenyl can be in the E or Z configuration. Alkenyl groups can be substituted by alkyl groups, as defined above or by halogen atoms.
The term "alkynyl", as used herein, refers to a monovalent or divalent hydrocarbon radical having 2 to 6 carbon atoms, derived from a saturated alkyl, having at least one triple bond. One methylene (-CH2-) group, of the alkynyl can be replaced by oxygen, sulfur, sulfoxide, nitrogen, carbonyl, carboxyl, sulfonyl, sulfate, sulfonate, amide, sulfonamide, by a divalent C 3-8 cycloalkyl, by a divalent heterocycle, or by a divalent aryl group. Alkynyl groups can be substituted by alkyl groups, as defined above, or by halogen atoms.
The term "heterocycle" as used herein, refers to a 3 to 10 membered ring, which can be aromatic or non-aromatic, saturated or unsaturated, containing at least one heteroatom selected form oxygen, nitrogen, sulfur, or combinations of at least two thereof, interrupting the carbocyclic ring structure. The heterocyclic ring can be interrupted by a C=0; the S and N heteroatoms can be oxidized. Heterocycles can be monocyclic or polycyclic. Heterocyclic ring moieties can be substituted by halogen atoms, sulfonyl groups, sulfoxide groups, nitro groups, cyano groups, -OC1-6 alkyl groups, -SCi-6 alkyl groups, -Ci-8 alkyl groups, -C2-6 alkenyl groups, - C2-6 alkynyl groups , ketone groups, alkylamino groups, amino groups, aryl groups, C3-8 cycloalkyl groups or hydroxyl groups.
The term "aryl" as used herein, refers to an organic moiety derived from an aromatic hydrocarbon consisting of a ring containing 6 to 10 carbon atoms, by removal of one hydrogen atom. Aryl can be substituted by halogen atoms, sulfonyl C1-6 alkyl groups, sulfoxide C1-6 alkyl groups, sulfonamide groups, carboxcyclic acid groups, Ci-6 alkyl carboxylates (ester) groups, amide groups, nitro groups, cyano groups, -OCi-6 alkyl groups, -SCi-6 alkyl groups, -Ci-6 alkyl groups, -C2-6 alkenyl groups, - C2-6 alkynyl groups , ketone groups, aldehydes, alkylamino groups, amino groups, aryl groups, C3-8 cycloalkyl groups or hydroxyl groups. Aryls can be monocyclic or polycyclic.
The term "hydroxyl" as used herein, represents a group of formula "-OH".
The term "carbonyl" as used herein, represents a group of formula "-C(O)-". The term "ketone" as used herein, represents an organic compound having a carbonyl group linked to a carbon atom such as -(CO)Rx wherein Rx can be alkyl, aryl, cycloalkyl, cycloalkenyl, heterocycle as defined above.
The term "amine" as used herein, represents a group of formula "-NRxRy ",wherein Rx and Ry can be the same or independently H, alkyl, aryl, cycloalkyl, cycloalkenyl, heterocycle as defined above.
The term "carboxyl" as used herein, represents a group of formula "-C(0)0-".
The term "sulfonyl" as used herein, represents a group of formula "-SO2 "".
The term "sulfate" as used herein, represents a group of formula "-0-S(0)2-0- ".
The term "sulfonate" as used herein, represents a group of the formula "-S(0)2-
0-".
The term "carboxylic acid" as used herein, represents a group of formula "- C(0)OH".
The term "nitro" as used herein, represents a group of formula "-NO2".
The term "cyano" as used herein, represents a group of formula "-CN".
The term "amide" as used herein, represents a group of formula "-C(0)NRxRy " wherein Rx and Ry can be the same or independently H, alkyl, aryl, cycloalkyl, cycloalkenyl, heterocycle as defined above.
The term "sulfonamide" as used herein, represents a group of formula "-
S(0)2NRxRy" wherein Rx and Ry can be the same or independently H, alkyl, aryl, cycloalkyl, cycloalkenyl, heterocycle as defined above.
The term "sulfoxide" as used herein, represents a group of formula "-S(O)-". The term "phosphonic acid" as used herein, represents a group of formula "- P(0)(OH)2".
The term "phosphoric acid" as used herein, represents a group of formula "- OP(0)(OH)2".
The term "sulphonic acid" as used herein, represents a group of formula "- S(0)2OH".
The formula Ή ", as used herein, represents a hydrogen atom.
The formula "O ", as used herein, represents an oxygen atom.
The formula "N ", as used herein, represents a nitrogen atom.
The formula "S ", as used herein, represents a sulfur atom. In another aspect, agonists of FPR2 are compounds selected from Table 1 :
Table 1
Figure imgf000023_0001
Figure imgf000024_0001
US 2005/0137230 A1 and US 7820673 disclose inhibitors of coagulation Factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and or the treatment of tumors. 2-({[(4-chlorophenyl)amino]carbonyl}amino)-3- phenylpropanoic acid, (2S)-2-({[(4-methoxyphenyl)amino]carbonyl}amino)-3- phenylpropanoic acid, (2S)-3-phenyl-2-[({[4-(trifluoromethyl)phenyl]amino} carbonyl)amino]propanoic acid, methyl 2-({[(4-iodophenyl)amino]carbonyl}amino)-3- phenylpropanoate, (2S)-2-({[(4-bromophenyl) amino]carbonyl}amino)-3- phenylpropanoic acid, (2R)-2-({[(4-bromophenyl)amino] carbonyl}amino)-3- phenylpropanoic acid, are intermediates in the synthesis of urea derivatives as activated blood coagulation factor X (FXa) inhibitors. JP 63232846 discloses the resolution of N-(p-bromophenylcarbamyl) derivatives ((2S)-2-({[(4-bromophenyl)amino]carbonyl}amino)-3-phenylpropanoic acid, (2S.3S)-
2- ({[(4-bromophenyl)amino]carbonyl}amino)-3-methylpentanoic acid, 2-({[(4- bromophenyl)amino]carbonyl}amino)-3-(1 H-indol-3-yl)propanoic acid, (2S)-2-({[(4- bromophenyl)amino]carbonyl}amino)-3-methylbutanoic acid) on HPLC column with novel chromatographic chiral stationary phases.
Journal of Chromatography (1987), 404(1 ), 1 17-22 and Chromatographia (1987), 23(10), 727-30 describe the resolution of p-Bromophenylcarbamyl derivatives of enantiomeric protein amino acids ((2R)-2-({[(4-bromophenyl)amino]carbonyl}amino)-
3- phenylpropanoic acid, (2S)-2-({[(4-bromophenyl)amino]carbonyl}amino)-3- phenylpropanoic acid), on novel chiral stationary phase by elution with an aqueous mobile phase. Biochimica et Biophysica Acta, Nucleic Acids and Protein Synthesis (1972), 272(4), 667-71 describes compound (2S)-2-({[(4-nitrophenyl)amino]carbonyl}amino)-3- phenylpropanoic acid) in poly(uridylic acid)-dependent binding of para nitrophenyl- carbamyl-phenylalanyl tRNA . In another aspect, agonists of FPR2 are compounds selected from Table 2:
Table 2
Figure imgf000025_0001
Figure imgf000026_0001
p enyet y m azo n- -y urea
Compounds of Table 2 are available from Chemical Libraries such as Aurora Fine Chemicals.
In another aspect, agonists of FPR2 are compounds selected from Table 3:
Table 3
Figure imgf000026_0002
Figure imgf000027_0001
Figure imgf000028_0001
The compounds of Table 3 are available from Chemical Libraries such as Chemical Block Ltd.
In a further embodiment of the invention, there are provided methods for treating disorders associated with modulation of the N-formyl peptide receptor like-1 receptor.
Such methods can be performed, for example, by administering to a subject in need thereof a pharmaceutical composition containing a therapeutically effective amount of at least one compound of the invention.
Therapeutic utilities of the N-formyl peptide receptor like-1 receptor modulators are dermatological inflammation and diseases including, but not limited to, dermal wound healing, hypertrophic scars, keloids, burns, rosacea, atopic dermatitis, acne, psoriasis, seborrheic dermatitis, actinic keratoses, basal cell carcinoma, squamous cell carcinoma, melanoma, viral warts, photoaging, photodamage, melasma, post-inflammatory hyperpigmentation, other disorders of pigmentation, and alopecia (scarring and non-scarring forms). These compounds are useful for the treatment of mammals, including humans, with a range of conditions and diseases that are alleviated by the N-formyl peptide receptor like-1 receptor modulation: dermatological inflammation and diseases including, but not limited to, dermal wound healing, hypertrophic scars, keloids, burns, rosacea, atopic dermatitis, acne, psoriasis, seborrheic dermatitis, actinic keratoses, basal cell carcinoma, squamous cell carcinoma, melanoma, viral warts, photoaging, photodamage, melasma, post-inflammatory hyperpigmentation, other disorders of pigmentation, and alopecia (scarring and non-scarring forms).
In still another embodiment of the invention, there are provided methods for treating disorders associated with modulation of the FPRL-1 receptor. Such methods can be performed, for example, by administering to a subject in need thereof a therapeutically effective amount of at least one compound of the invention, or any combination thereof, or pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual isomers, enantiomers, and diastereomers thereof.
The actual amount of the compound to be administered in any given case will be determined by a physician taking into account the relevant circumstances, such as the severity of the condition, the age and weight of the patient, the patient's general physical condition, the cause of the condition, and the route of administration.
The patient will be administered the compound orally in any acceptable form, such as a tablet, liquid, capsule, powder and the like, or other routes may be desirable or necessary, particularly if the patient suffers from nausea. Such other routes may include, without exception, transdermal, parenteral, subcutaneous, intranasal, via an implant stent, intrathecal, intravitreal, topical to the eye, back to the eye, intramuscular, intravenous, and intrarectal modes of delivery. Additionally, the formulations may be designed to delay release of the active compound over a given period of time, or to carefully control the amount of drug released at a given time during the course of therapy.
In another embodiment of the invention, there are provided pharmaceutical compositions including at least one compound of the invention in a pharmaceutically acceptable carrier thereof. The phrase "pharmaceutically acceptable" means the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. Pharmaceutical compositions of the present invention can be used in the form of a solid, a solution, an emulsion, a dispersion, a patch, a micelle, a liposome, and the like, wherein the resulting composition contains one or more compounds of the present invention, as an active ingredient, in admixture with an organic or inorganic carrier or excipient suitable for enteral or parenteral applications. Invention compounds may be combined, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, and any other form suitable for use. The carriers which can be used include glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea, medium chain length triglycerides, dextrans, and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form. In addition auxiliary, stabilizing, thickening and coloring agents and perfumes may be used. Invention compounds are included in the pharmaceutical composition in an amount sufficient to produce the desired effect upon the process or disease condition.
Pharmaceutical compositions containing invention compounds may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of a sweetening agent such as sucrose, lactose, or saccharin, flavoring agents such as peppermint, oil of wintergreen or cherry, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets containing invention compounds in admixture with non-toxic pharmaceutically acceptable excipients may also be manufactured by known methods. The excipients used may be, for example, (1 ) inert diluents such as calcium carbonate, lactose, calcium phosphate or sodium phosphate; (2) granulating and disintegrating agents such as corn starch, potato starch or alginic acid; (3) binding agents such as gum tragacanth, corn starch, gelatin or acacia, and (4) lubricating agents such as magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.
In some cases, formulations for oral use may be in the form of hard gelatin capsules wherein the invention compounds are mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin. They may also be in the form of soft gelatin capsules wherein the invention compounds are mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.
Pharmaceutical compositions containing invention compounds may be in a form suitable for topical use, for example, as oily suspensions, as solutions or suspensions in aqueous liquids or nonaqueous liquids, or as oil-in-water or water-in- oil liquid emulsions.
The pharmaceutical compositions may be in the form of a sterile injectable suspension. This suspension may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1 ,3- butanediol. Sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides, fatty acids (including oleic acid), naturally occurring vegetable oils like sesame oil, coconut oil, peanut oil, cottonseed oil, etc., or synthetic fatty vehicles like ethyl oleate or the like. Buffers, preservatives, antioxidants, and the like can be incorporated as required.
The compounds of the invention may also be administered in the form of suppositories for rectal administration of the drug. These compositions may be prepared by mixing the invention compounds with a suitable non-irritating excipient, such as cocoa butter, synthetic glyceride esters of polyethylene glycols, which are solid at ordinary temperatures, but liquefy and/or dissolve in the rectal cavity to release the drug.
Since individual subjects may present a wide variation in severity of symptoms and each drug has its unique therapeutic characteristics, the precise mode of administration and dosage employed for each subject is left to the discretion of the practitioner. The compounds and pharmaceutical compositions described herein are useful as medicaments in mammals, including humans, for treatment of diseases and/or alleviations of conditions which are responsive to treatment by agonists or functional antagonists of the N-formyl peptide receptor like-1 (FPRL-1 ) receptor. Thus, in further embodiments of the invention, there are provided methods for treating a disorder associated with modulation of the N-formyl peptide receptor like-1 (FPRL-1 ) receptor. Such methods can be performed, for example, by administering to a subject in need thereof a pharmaceutical composition containing a therapeutically effective amount of at least one invention compound. As used herein, the term "therapeutically effective amount" means the amount of the pharmaceutical composition that will elicit the biological or medical response of a subject in need thereof that is being sought by the researcher, veterinarian, medical doctor or other clinician. In some embodiments, the subject in need thereof is a mammal. In some embodiments, the mammal is human.
Materials and Methods
FPR2 agonists would be expected to have significant effects in many different types of dermatological inflammation, but have been exemplified by demonstrating wound healing in a mouse model of punch dermal wound (Figure 2). Antiinflammatory activity in this model has been exemplified with the FPR2 agonists described in Table 4.
FLIPR: HEK-Ga16 cells stably expressing the human FPR2 receptor was utilized. Cells were plated into 384-well poly-D-lysine coated plates at a density of 18,000 cells per well one day prior to use. The growth media was DMEM medium
supplemented with 10% fetal bovine serum (FBS), 1 % antibiotic-antimycotic, 50 μg/ml hygromycin, and 400 μg/ml geneticin. On the day of the experiment, the cells were washed twice with Hank's Balanced Salt Solution supplemented with 20 mM HEPES (HBSS/hepes buffer). The cells were then dye loaded with 2 μΜ Fluo-4 diluted in the HBSS/Hepes buffer and incubated at 37°C for 40 minutes.
Extracellular dye was removed by washing the cell plates four times prior to placing the plates in the FLIPR (Fluorometric Imaging Plate Reader, Molecular Devices). Ligands were diluted in HBSS/Hepes buffer and prepared in 384-well microplates. Data for Ca+2 responses were obtained in relative fluorescence units.
Table 4
Figure imgf000033_0001
Figure imgf000034_0001
Figure imgf000035_0001
Figure imgf000036_0001
Figure imgf000037_0001
(methylsulfanyl)phenyl]urea
Figure imgf000038_0001
Figure imgf000039_0001
Figure imgf000040_0001
no}pentanoic acid (1.0)
Figure imgf000041_0001
Figure imgf000043_0001
Figure imgf000044_0001
Figure imgf000045_0001
Figure imgf000046_0001
Figure imgf000047_0001
}methyl)phosphonate
Figure imgf000048_0001
Br yl)ethyl]benzoic acid
Figure imgf000049_0001
Figure imgf000050_0001
Immunohistochemistry: Fluorescent immunohistochemistry with antibodies specific to FPR2 was used to determine localization in normal human skin. Anti-FPR2 antibody (Abeam) was used at a dilution of 1 :200 to detect FPR2 protein.
Dermal wound healing model: Groups of 5 ICR male mice weighing 24-28 g were used. During the study, the tested animals were housed in individual cages. Under hexobarbital (90 mg/kg, i.p.) anesthesia, the shoulder and back region of each animal was shaved. A sharp punch (ID 12 mm) was applied to remove the skin including panniculus carnosus and adherent tissues. The wound area, traced onto clear plastic sheets, was measured by use of an Image - ProPlus (Media
Cybernetics, Version 4.5.0.29) on days 1 , 3, 5, 7, 9 and 1 1 . Test substances and vehicle (Placebo, 20 μΙ-Ληουββ) were administered topically (TOP) once daily post skin punch for a total of 10 consecutive days. The positive control of CGS-21680 in 0.5% CMC/PBS, pH 7.4 was given topically as the same regimen. The percent closure of the wound (%) was calculated, and wound half-closure time (CT50) was analyzed by linear regression using Graph-Prism (Graph Software USA). One-way ANOVA followed by Dunnett's test was applied for comparison between the treated and vehicle groups at each measurement time point. Differences are considered significant at P<0.05. LL37-induced model of Rosacea in mice: Prior to dosing, animals are lightly anaesthetized with isofluorane and baseline right and left ear thickness measurements are made with a digital caliper (Mitutoyo 293-340). At t = -1 hrs, animals are lightly anaesthetized with isoflurane to allow topical application (dorsal side) of 10 μΙ_ of FPR2 agonist formulated in a vehicle consisting of PBS:ethanol (50:50), or vehicle control to both ears. At t = 0 hr, mice are re-anaesthetized. Following ear thickness measurements, 20 uL of LL-37 (100 μΜ) is injected into the right ear, while PBS is injected into the left ear. Additional ear thickness measurements are taken at t = 3 and 6 hours.
After the last time point, mice are euthanized by C02 inhalation and ears collected for additional analyses.
In vitro human skin penetration model: Briefly, split-thickness human abdominal skin (-0.50 mm) sections from two donors were mounted in flow-through diffusion cells (PermeGear). FPR2 agonists are applied at a dose of 10 μΙ_ to a surface area of 0.64 cm2 (n=7 per compound). PBS is pumped beneath the skin at a constant flow rate of -42 μΙ_Ληίη. Receptor fluid samples are collected at 1 , 3, 6, 12, and 24 hrs and analyzed by LC/MS/MS.

Claims

What is claimed is:
1 . A method of treating dermal inflammation and dermal diseases by local or systemic delivery, in a subject in need of such treatment, which comprises administering a
5 pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2.
2. The method of claim 1 , wherein the dermal inflammation and dermal diseases are selected from: dermal wound healing, hypertrophic scars, keloids, burns, rosacea,
10 atopic dermatitis, acne, psoriasis, seborrheic dermatitis, actinic keratoses, basal cell carcinoma, squamous cell carcinoma, melanoma, viral warts, photoaging, photodamage, melasma, post-inflammatory hyperpigmentation, disorders of pigmentation, alopecia, scarring and non-scarring forms.
153. The method of claim 1 , wherein the agonist of FPR2 is represented by Formula I
Figure imgf000052_0001
Formula I
0 wherein:
R1 is sec-butyl, C6-io aryl, -CH2- (C6-io)aryl, -CH2-heterocycle, C -8 cycloalkyl or C3-8 cycloalkenyl or heterocycle;
R2 is halogen or methyl;
R3 is halogen;
5 R4 is H, methyl or halogen;
R5 is OR6 or NH2; and
R6 is H or C2-4 alkyl.
4. The method of claim 3, wherein the agonist of FPR2 is selected from:
(2S,3S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-3-methylpentanoic acid; 30 (2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanoic acid;
(2S)-2-{[(4-bromophenyl)carbamoyl]amino}pentanoic acid;
(2S)-2-{[(4-iodophenyl)carbamoyl]amino}-4-methylpentanoic acid; and (2S)-4-methyl-2-({[4-(methylsulfanyl)phenyl]carbamoyl}amino)pentanoic acid.
5. The method of claim 1 , wherein the agonist of FPR2 is represented by
Formula II :
Figure imgf000053_0001
Formula II
wherein:
a is 1 and b is 0;
a is O and b is l ;
a is 1 and b is 1 ;
R1 is optionally substituted Ci-8 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C-6-10 aryl, optionally substituted C3-8 cycloalkenyl, -NR11R12 or -OR13;
R2 is optionally substituted Ci-8 alkyl or optionally substituted C6-io aryl;
R3 is hydrogen, optionally substituted Ci-8 alkyl, halogen, -COOR15, - OR13, - NR11R12, N02, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-io aryl or optionally substituted C3-8 cycloalkenyl; R4 is hydrogen, optionally substituted Ci-8 alkyl, halogen, - COOR15, - OR13, - NR11R12, N02, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl or optionally substituted C3-8 cycloalkenyl; R5 is halogen, -CF3 or -S(0)nR14;
n is 0, 1 or 2;
R6 is hydrogen, optionally substituted Ci-8 alkyl, halogen, - COOR15, - OR13, - NR11R12, N02, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-io aryl or optionally substituted C3-8 cycloalkenyl; R7 is hydrogen, optionally substituted Ci-8 alkyl, halogen, - COOR15, - OR13, - NR11R12, N02, optionally substituted heterocycle, optionally substituted C3-8 cycloalkyl, optionally substituted C6-io aryl or optionally substituted C3-8 cycloalkenyl; R is hydrogen, optionally substituted Ci-8 alkyl or optionally substituted C6-io aryl; R9 is hydrogen, optionally substituted Ci-8 alkyl or optionally substituted C6-io aryl; R10 is hydrogen, optionally substituted Ci-8 alkyl or optionally substituted C6-io aryl; R9a is hydrogen, optionally substituted C-i-s alkyl or optionally substituted C-6-10 aryl; R10a is hydrogen, optionally substituted Ci-8 alkyl or optionally substituted C6-io aryl; R11 is hydrogen or optionally substituted -e alkyl;
R12 is hydrogen or optionally substituted d-e alkyl;
R13 is hydrogen or optionally substituted d-e alkyl;
R14 is hydrogen, CF3 or optionally substituted Ci-8 alkyl; and
R15 is hydrogen or optionally substituted d-e alkyl.
6. The method of claim 5, wherein the agonist of FPR2 is selected from:
{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}pentanoyl]amino}acetic acid;
{[(2S,3S)-2-{[(4-bromophenyl)carbamoyl]amino}-3-methylpentanoyl]amino}acetic acid;
(2S,3S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-3-methylpentanoic acid; 2-{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}-2- methylpropanoic acid;
{[(2S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-4-methylpentanoyl] amino}acetic acid;
{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}acetic acid; 2-{[(4-bromophenyl)carbamoyl]amino}-N-(2-oxoazepan-3-yl)-3-phenylpropanamide; {[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-3-phenylpropanoyl]amino}acetic acid; 3-{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-3-phenylpropanoyl]amino}propanoic acid;
(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-N-(2-hydroxyethyl)-3- phenylpropanamide;
{[(2S,3S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-3- methylpentanoyl]amino}acetic acid;
(2S,3S)-N-(2-amino-2-oxoethyl)-2-{[(4-bromophenyl)carbamoyl]amino}-3- methylpentanamide;
(2S,3S)-N-(2-amino-2-oxoethyl)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-3- methylpentanamide; (2S,3S)-2-{[(4-bromophenyl)carbamoyl]amino}-3-methyl-N-(2- oxopropyl)pentanamide;
(2S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-N-(2-oxopropyl)-3- phenylpropanamide;
(2S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-N-(2-hydroxyethyl)-3- phenylpropanamide;
methyl {[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}pentanoyl]amino}acetate; propan-2-yl {[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}pentanoyl]amino}acetate; {[(2S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}pentanoyl]amino}acetic acid; (2S)-2-{[(4-bromophenyl)carbamoyl]amino}-N-(2-hydroxyethyl)-4- methylpentanamide;
(2S)-N-(2-amino-2-oxoethyl)-2-{[(4-bromophenyl)carbamoyl]amino}-4- methylpentanamide;
(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methyl-N-(2-oxopropyl)pentanamide; (2S)-N-(2-amino-2-oxoethyl)-2-{[(4-bromophenyl)carbamoyl]amino}pentanamide; (2S)-N-(2-amino-2-oxoethyl)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]
amino}pentanamide;
(2S)-N-(2-amino-2-oxoethyl)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-4- methylpentanamide;
(2S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-4-methyl-N-(2- oxopropyl)pentanamide;
(2S)-2-{[(2S)-2-{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-4-methylpentanoyl] amino}propanoic acid;
(2S)-2-{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanoyl] amino}propanoic acid;
(2S)-2-{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}-3- methylbutanoic acid;
(2S)-N-[(2S)-1 -amino-3-methyl-1 -oxobutan-2-yl]-2-{[(4-bromophenyl)carbamoyl] amino}-4-methylpentanamide;
(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-N-(2-hydroxy-2-methylpropyl)-4- methylpentanamide;
(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-N-(1 ,3-dihydroxypropan-2-yl)-4- methylpentanamide; (2S)-2-{[(4-bromophenyl)carbamoyl]amino}-N-(2,3-dihydroxypropyl)-4- methylpentanamide;
(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-N-[(2R)-1 -hydroxypropan-2-yl]-4- methylpentanamide;
tert-butyl (2S)-2-{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4- methylpentanoyl]amino}pentanoate;
(2S)-2-{[(2S)-2-{[(4-bromophenyl)carbamoyl]a;mino}-4-methylpentanoyl]amin pentanoic acid
(2S)-N-[(2S)-1 -amino-1 -oxopentan-2-yl]-2-{[(4-bromophenyl)carbamoyl]amino}-4- methylpentanamide;
(2S)-{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanoyl]amino}
(phenyl)ethanoic acid;
(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methyl-N-(1 H-tetrazol-5- ylmethyl)pentanamide;
[(2-{[(4-bromophenyl)carbamoyl]amino}-2,4-dimethylpentanoyl)amino]acetic acid; (2-{[(4-bromophenyl)carbamoyl]amino}-2-ethylbutanoyl)amino]acetic acid;
(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-N-[(3-hydroxy-1 ,2-oxazol-5-yl)methyl]-4- methylpentanamide;
(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-N-^
methylpentanamide;
{[(2S)-4-methyl-2-({[4-(thfluoromethyl)phenyl]carbamoyl}amino)pentanoyl] amino}acetic acid;
{[(2S)-4-methyl-2-({[4-(methylsulfanyl)phenyl]carbamoyl}amino)pentanoyl] amino}acetic acid;
(2S)-4-methyl-N-(1 H-tetrazol-5-ylmethyl)-2-({[4-(trifluoromethyl)phenyl]carbamoyl} amino)pentanamide;
2-methyl-2-{[(2S)-4-methyl-2-({[4-(thfluoromethyl)phenyl]carbamoyl}amino)pentanoyl] amino}propanoic acid;
{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-(methylsulfanyl)butanoyl]amino}acetic acid;
{[2-{[(4-bromophenyl)carbamoyl]amino}-3-(1 H-indol-3-yl)propanoyl]amino}acetic acid;
tert-butyl {[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanoyl](methyl) amino}acetate; and {[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4-methylpentanoyl](methyl)
amino}acetic acid.
7. The method of claim 1 , wherein the agonist of FPR2 is represented by
Formula III :
Figure imgf000057_0001
Formula III
R1 is halogen, hydrogen, optionally substituted C i-8 alkyl, OR9, C(0)R10, N02, NR13R14, CN, SR15 or S02R16;
R2 is halogen, optionally substituted C i-8 alkyl, CF3, OR9, C(0)R10, N02, NR13R14, CN, SR15 or S02R16;
R3 is hydrogen, optionally substituted C i-8 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted C 6-io aryl, optionally substituted heterocycle, or together with R5 forms a 10- or 1 1 - membered polycyclic ring which is optionally substituted;
Figure imgf000057_0002
Figure imgf000058_0001
, , , optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted C 6-io aryl, optionally substituted heterocycle, or together with R5 forms a spiro monocyclic or polycyclic, carbocyclic or heterocyclic, saturated or unsaturated 5 to 10 member ring which is optionally substituted;
R5 is hydrogen, optionally substituted C i-8 alkyl, optionally substituted C3-8 cycloalkyl, optionally substituted C3-8 cycloalkenyl, optionally substituted C 6-io aryl, optionally substituted heterocycle, or together with R4 forms a spiro monocyclic or polycyclic carbocyclic or heterocyclic, saturated or unsaturated 5 to 10 member ring which is optionally substituted or together with R3 forms a 5 or 6 member ring which is optionally substituted;
halogen, hydrogen, optionally substituted C i-8 alkyl, OR9, C(0)R10, N02,
NR13R14, CN, SR15 or S02R16;
R7 is halogen, hydrogen, optionally substituted C i-8 alkyl, OR9, C(0)R10, N02,
15
NR13R14, CN, SR lo or S02R >1ID6;. R8 is halogen, hydrogen, optionally substituted C i-8 alkyl, OR9, C(0)R10, N02, NR13R14, CN, SR15 or S02R16;
R9 is hydrogen, C(0)(Ci-8 alkyl) or optionally substituted C i-8 alkyl;
R10 is hydrogen, optionally substituted C i-8 alkyl, 0(C i-8 alkyl), NR11R12 or OH;
R11 is hydrogen, optionally substituted C 6-io aryl or optionally substituted C i-8 alkyl; R12 is hydrogen, optionally substituted C 6-io aryl or optionally substituted C i-8 alkyl; R13 is hydrogen, optionally substituted C 6-io aryl or optionally substituted C i-8 alkyl; R14 is hydrogen, optionally substituted C 6-io aryl, optionally substituted C i-8 alkyl, C(0)(C 1-s alkyl) or S02(C i-8 alkyl);
R15 is hydrogen, optionally substituted C i-8 alkyl or 0(C i-8 alkyl);
R16 is OH, 0(C 1-s alkyl), (C i-8 alkyl) or NR11R12;
R17 is hydrogen, optionally substituted C 6-io aryl or optionally substituted C i-8 alkyl; R18 is hydrogen, C(0)(Ci-8 alkyl), optionally substituted C 6-io aryl, or optionally substituted C i-8 alkyl;
R19 is hydrogen, C(0)(Ci-8 alkyl), optionally substituted C 6-io aryl or optionally substituted C i-8 alkyl;
R20 is hydrogen, optionally substituted C 6-io aryl or optionally substituted C i-8 alkyl; R21 is hydrogen, optionally substituted C 6-io aryl or optionally substituted C i-8 alkyl; n is 1 , 2, 3, 4, or 5;
m is 1 , 2, 3, 4, or 5.
8. The method according to claim 7, wherein the FPR2 agonist is selected from:
1 -(4-bromophenyl)-3-[4-ethyl-2,5-dioxo-4-(2-phenylethyl)imidazolidin-1 -yl]urea; 1 -(4-bromophenyl)-3-[4-ethyl-2,5-dioxo-4-(propan-2-yl)imidazolidin-1 -yl]urea;
1-(4-bromophenyl)-3-(4,4-diethyl-2,5-dioxoimidazolidin-1-yl)urea;
1-(4-bromo-2-fluorophenyl)-3-(4,4-diethyl-2,5-dioxoimidazolidin-1-yl)urea;
1-(4-bromophenyl)-3-(2,4-dioxo-1 ,3-diazaspiro[4.5]dec-3-yl)urea;
1-(4-bromophenyl)-3-[4-methyl-2,5-dioxo-4-(2-phenylethyl)imidazolidin-1-yl]urea; 1 -(4-bromophenyl)-3-[4-methyl-2,5-dioxo-4-(2-phenylethyl)imidazolidin-1 -yl]urea;
1-(4-bromo-2-fluorophenyl)-3-[4-ethyl-2,5-dioxo-4-(propan-2-yl)imidazolidin-1- yl]urea;
1-(4-bromophenyl)-3-[2,5-dioxo-4,4-di(propan-2-yl)imidazolidin-1-yl]urea;
1-(4-bromophenyl)-3-(4,4-dicyclopropyl-2,5-dioxoimidazolidin-1-yl)urea; 1 -(4-bromophenyl)-3-[4-ethyl-2,5-dioxo-4-(propan-2-yl)imidazolidin-1 -yl]urea; 1 -(4-bromophenyl)-3-[4-ethyl-2,5-dioxo-4-(propan-2-yl)imidazolidin-1 -yl]urea; 1 -(4-bromo-2-fluorophenyl)-3-[4-ethyl-2,5-dioxo-4-(2-phenylethyl)imidazolidin-1 - yl]urea;
1 -(4-bromophenyl)-3-{4-[2-(furan-2-yl)ethyl]-4-methyl-2,5-dioxoimidazolidin-1 - yl}urea;
1 -(4-bromophenyl)-3-{4-[2-(4-fluorophenyl)ethyl]-4-methyl-2,5-dioxoimidazolidin- 1 -yl}urea;
1 -(4-bromophenyl)-3-{4-[2-(3-fluorophenyl)ethyl]-4-methyl-2,5-dioxoimidazolidin- 1 -yl}urea;
1 -(4-bromophenyl)-3-{4-[2-(4-hydroxyphenyl)ethyl]-4-methyl-2,5- dioxoimidazolidin-1 -yl}urea;
1 -(4-bromophenyl)-3-{4-methyl-2,5-dioxo-4-[2-(thiophen-2-yl)ethyl]imidazolidin-1 - yl}urea;
1 -(4-bromo-2-fluorophenyl)-3-{4-[2-(4-hydroxyphenyl)ethyl]-4-methyl-2,5- dioxoimidazolidin-1 -yl}urea;
1 -(4-bromophenyl)-3-{4-methyl-4-[2-(5-methylfuran-2-yl)ethyl]-2,5- dioxoimidazolidin-1 -yl}urea;
1 -(4-bromo-2-fluorophenyl)-3-{4-[2-(3-fluoro-4-hydroxyphenyl)ethyl]-4-methyl-2,5- dioxoimidazolidin-1 -yl}urea;
1 -(4-bromophenyl)-3-{4-[2-(3-fluoro-4-hydroxyphenyl)ethyl]-4-methyl-2,5- dioxoimidazolidin-1 -yl}urea;
1 -(4-bromo-2-fluorophenyl)-3-{4-[2-(2-hydroxyphenyl)ethyl]-4-methyl-2,5- dioxoimidazolidin-1 -yl}urea;
1 -(4-bromo-2-fluorophenyl)-3-{4-[2-(3-hydroxyphenyl)ethyl]-4-methyl-2,5- dioxoimidazolidin-1 -yl}urea;
1 -(4-bromophenyl)-3-{4-[2-(3-hydroxyphenyl)ethyl]-4-methyl-2,5- dioxoimidazolidin-1 -yl}urea;
1 -(4-bromophenyl)-3-{4-[2-(2-hydroxyphenyl)ethyl]-4-methyl-2,5- dioxoimidazolidin-1 -yl}urea;
1 - (4-bromophenyl)-3-[4-(hydroxymethyl)-2,5-dioxo-4-(propan-2-yl)imidazolidin-1 - yl]urea;
2- [1 -{[(4-bromophenyl)carbamoyl]amino}-2,5-dioxo-4-(propan-2-yl)imidazolidin-4- yl]-N-(2-hydroxyethyl)acetamide; methyl 2-[2-(1 -{[(4-bromophenyl)carbamoyl]amino}-4-ethyl-2,5-dioxoimidazolidin- 4-yl)ethyl]benzoate;
2-[1 -{[(4-bromophenyl)carbamoyl]amino}-2,5-dioxo-4-(propan-2-yl)imidazolidin-4- yl]-N-(1 ,3-dihydroxypropan-2-yl)acetamide;
2-[2-(1 -{[(4-bromophenyl)carbamoyl]amino}-4-ethyl-2,5-dioxoimidazolidin-4- yl)ethyl]benzoic acid;
2- [2-(1 -{[(4-bromo-2 -fluorophenyl )carbamoyl]amino}-4-ethyl-2, 5- dioxoimidazolidin-4-yl)ethyl]benzoic acid;
3- ({[1 -{[(4-bromophenyl)carbamoyl]amino}-2,5-dioxo-4-(propan-2-yl)imidazolidin- 4-yl]acetyl}amino)propanoic acid;
2-[1 -{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-2,5-dioxo-4-(propan-2- yl)imidazolidin-4-yl]-N-(2-hydroxyethyl)acetamide;
2- {2-[1 -{[(4-bromophenyl)carbamoyl]amino}-2,5-dioxo-4-(propan-2- yl)imidazolidin-4-yl]ethyl}benzoic acid;
diethyl [2-({[1 -{[(4-bromophenyl)carbamoyl]amino}-2,5-dioxo-4-(propan-2- yl)imidazolidin-4-yl]acetyl}amino)ethyl]phosphonate;
ethyl 3-{[(4-bromophenyl)carbamoyl]amino}-2,4-dioxo-1 ,3-diazaspiro[4.5]decane- 8-carboxylate;
1 -(4-bromophenyl)-3-{4-[2-(2-fluorophenyl)ethyl]-4-methyl-2,5-dioxoimidazolidin- 1 -yl}urea; and
3- ({[1 -{[(4-bromo-2-fluorophenyl)carbamoyl]amino}-2,5-dioxo-4-(propan-2- yl)imidazolidin-4-yl]acetyl}amino)propanoic acid.
9. The method according to claim 1 , wherein the agonist of FPR2 is represented by Formula VII :
Figure imgf000061_0001
Formula VII
wherein:
n is 0 or 1 ;
R1 is hydrogen, substituted or unsubstituted Ci-8 alkyl, halogen, -NR8R9, -NC(0)R20, - OR10, -OC(0)R21 -SR11 , -C(0)R12, CN or N02;
R2 is hydrogen, substituted or unsubstituted Ci-8 alkyl, halogen, - NR8R9, -NC(0)R20 , -OR10, -OC(0)R21 ' -SR 11, -C(0)R12, CN or N02;
R3 is hydrogen, substituted or unsubstituted Ci-8 alkyl, halogen, - NR8R9, -NC(0)R20 , -OR10, -OC(0)R21 , -SR11 , -C(0)R12, CN, N02, CF3, S(0)R15 or S(0)2R16;
R4 is hydrogen, substituted or unsubstituted Ci-8 alkyl, halogen, - NR8R9, -NC(0)R20■ -OR10, -OC(0)R21 , -SR11 , -C(0)R12, CN or N02;
R5 is hydrogen, substituted or unsubstituted Ci-8 alkyl, halogen, - NR8R9, -NC(0)R20 -OR10, -OC(0)R21 , SR11 , -C(0)R12, CN or N02;
R6 is hydrogen, substituted or unsubstituted Ci-8 alkyl, substituted or unsubstituted heterocycle, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted
C6-io aryl, substituted or unsubstituted C3-8 cycloalkenyl or -CH2R19;
R7 is substituted or unsubstituted heterocycle, -SR11, -NR8R9 , -
N(H)C(0)N(H)S(0)2R19, -BR13R14, -S(0)R15, -C(0)N(H)(CN), -C(0)N(H)S(0)2R19, -
S(0)(N)(P03H2)-, -S(0)2R16 or -P(0)R17R18;
R8 is hydrogen, substituted or unsubstituted Ci-8 alkyl substituted or unsubstituted C3-
8 cycloalkyl, substituted or unsubstituted heterocycle, or substituted or unsubstituted
C6-io aryl;
R9 is hydrogen, substituted or unsubstituted C-i-8 alkyl substituted or unsubstituted
C3-8 cycloalkyl, substituted or unsubstituted heterocycle, or substituted or
unsubstituted C6-io aryl;
R10 is hydrogen or substituted or unsubstituted Ci-8 alkyl ;
R11 is hydrogen , substituted or unsubstituted Ci-8 alkyl or -CF3;
R12 is hydrogen, substituted or unsubstituted Ci-8 alkyl, hydroxyl, -OR24 or -NR8R9;
R13 is -OR22;
R14 is -OR23;
R15 is substituted or unsubstituted Ci-8 alkyl;
R16 is substituted or unsubstituted Ci-8 alkyl, -NR8R9 , -NHS(0)2R19 or hydroxyl;
R17 is OR10 or NR8R9;
R18 is OR10 or NR8R9; R19 is substituted or unsubstituted heterocycle, substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted C6-io aryl or substituted or unsubstituted C3-8 cycloalkenyl;
R20 is hydrogen, substituted or unsubstituted d-e alkyl substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted heterocycle, or substituted or unsubstituted C6-io aryl;
R21 is hydrogen, substituted or unsubstituted d-e alkyl substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted heterocycle, or substituted or unsubstituted C6-io aryl;
R22 is hydrogen, substituted or unsubstituted d-e alkyl, or together with R23 can form a cycle;
R23 is hydrogen, substituted or unsubstituted d-e alkyl, or together with R22 can form a cycle;
R24 is hydrogen, substituted or unsubstituted d-e alkyl substituted or unsubstituted C3-8 cycloalkyl, substituted or unsubstituted heterocycle, or substituted or unsubstituted C6-io aryl.
10. The method of claim 9, wherein the FPR2 agonist is selected from:
{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}pentanoyl]amino}acetic acid;
2-{[(4-bromophenyl)carbamoyl]amino}-N-(2-oxoazepan-3-yl)-3-phenylpropanamide; ethyl hydrogen ({[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4- methylpentanoyl]amino}methyl)phosphonate;
diethyl ({[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4- methylpentanoyl]amino}methyl)phosphonate;
diethyl ({[(2S,3S)-2-{[(4-bromophenyl)carbamoyl]amino}-3- methylpentanoyl]amino}methyl)phosphonate;
ethyl hydrogen ({[(2S,3S)-2-{[(4-bromophenyl)carbamoyl]amino}-3- methylpentanoyl]amino}methyl)phosphonate;
diethyl ({[(2S)-2-{[(4- bromophenyl)carbamoyl]amino}pentanoyl]amino}methyl)phosphonate;
diethyl ({[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-3- phenylpropanoyl]amino}methyl)phosphonate; diethyl (2-{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4- methylpentanoyl]amino}ethyl)phosphonate;
ethyl hydrogen ({[(2S)-2-{[(4- bromophenyl)carbamoyl]amino}pentanoyl]amino}methyl)phosphonate;
dipropan-2-yl ({[(2S)-2-{[(4- bromophenyl)carbamoyl]amino}pentanoyl]amino}methyl)phosphonate;
ethyl hydrogen ({[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-3- phenylpropanoyl]amino}methyl)phosphonate;
{[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4- methylpentanoyl]amino}methanesulfonic acid;
propan-2-yl hydrogen {[(2-{[(4- bromophenyl)carbamoyl]amino}pentanoyl)amino]methyl}phosphonate;
dipropan-2-yl ({[(2S)-2-{[(4-bromophenyl)carbamoyl]amino}-4- methylpentanoyl]amino}methyl)phosphonate;
diethyl ({[(2S)-4-methyl-2-({[4-
(trifluoromethyl)phenyl]carbamoyl}amino)pentanoyl]amino}methyl)phosphonate; ethyl hydrogen ({[(2S)-4-methyl-2-({[4-
(trifluoromethyl)phenyl]carbamoyl}amino)pentanoyl]amino}methyl)phosphonate; {[(2S)-4-methyl-2-({[4- (trifluoromethyl)phenyl]carbamoyl}amino)pentanoyl]amino}methanesulfonic acid; and diethyl ({[(2S)-4-methyl-2-({[4-
(methylsulfanyl)phenyl]carbamoyl}amino)pentanoyl]amino}methyl)phosphonate.
1 1 . The method of claim 1 , wherein the FPR2 agonist is selected from:
2- ({[(4-chlorophenyl)amino]carbonyl}amino)-3-phenylpropanoic acid;
(2S)-2-({[(4-methoxyphenyl)amino]carbonyl}amino)-3-phenylpropanoic acid;
(2S)-3-phenyl-2-[({[4-(trifluoromethyl)phenyl]amino}carbonyl)amino]propanoic acid; (2S)-2-({[(3,4-dichlorophenyl)amino]carbonyl}amino)-3-phenylpropanoic acid;
(2S)-2-({[(4-nitrophenyl)amino]carbonyl}amino)-3-phenylpropanoic acid;
3- phenyl-2-[({[4-(trifluoromethoxy)phenyl]amino}carbonyl)amino]propanoic acid; 2-({[(3,4-dimethoxyphenyl)amino]carbonyl}amino)-3-phenylpropanoic acid;
methyl 2-({[(4-iodophenyl)amino]carbonyl}amino)-3-phenylpropanoate; (2S)-2-({[(4-bromophenyl)amino]carbonyl}amino)-3-phenylpropanoic acid;
(2R)-2-({[(4-bromophenyl)amino]carbonyl}amino)-3-phenylpropanoic acid;
3-phenyl-2-{[(pyridin-3-ylamino)carbonyl]amino}propanoic acid;
(2S,3S)-2-({[(4-bromophenyl)amino]carbonyl}amino)-3-methylpentanoic acid;
(2S)-({[(4-bromophenyl)amino]carbonyl}arnino)(phenyl)acetic acid;
2-({[(4-bromophenyl)amino]carbonyl}amino)-3-(1 H-indol-3-yl)propanoic acid;
(2S)-2-({[(4-bromophenyl)amino]carbonyl}amino)-3-methylbutanoic acid;
(2S)-2-({[(4-bromo-2-fluorophenyl)amino]carbonyl}amino)-3-methylbutanoic acid; 1 -(4-chlorophenyl)-3-(2,4-dioxo-1 ,3-diazaspiro[4,5]decan-3-yl) urea;
1 -(4-chlorophenyl)-3-(4-ethyl-4-methyl-2,5-dioxoimidazolidin-1 -yl)urea;
1 -[4-methyl-2,5-dioxo-4-(2-phenylethyl)imidazolidin-1 -yl]-3-phenylurea;
1 -(8-methyl-2,4-dioxo-1 ,3-diazaspiro[4,5]decan-3-yl)-3-(p-tolyl)urea;
1 - (2-fluorophenyl)-3-[4-methyl-2,5-dioxo-4-(2-phenylethyl)imidazolidin-1 -yl]urea; N-(4-bromophenyl)-2-(4,4-dimethyl-2,5-dioxoimidazolidin-1 -yl)acetamide;
N-(4-bromophenyl)-2-(4,4-diethyl-2,5-dioxoimidazolidin-1 -yl)acetamide;
N-(4-bromophenyl)-2-(2,4-dioxo-1 ,3-diazaspiro[4
N-(4-bromophenyl)-2-(2,5-dioxo-4,4-dipropylimidazolidin-1 -yl)acetamide;
N-(4-bromophenyl)-2-(4-ethyl-2,5-dioxo-4-phenylimidazolidin-1 -yl)acetamide;
N-(4-bromophenyl)-2-(4-cyclopropyl-4-methyl-2,5-dioxoimidazolidin-1 -yl)acetamide; N-(4-bromophenyl)-2-(2,4-dioxo-1 ,3-diazaspiro[4
N-(4-bromophenyl)-2-(4-ethyl-4-methyl-2,5-dioxoimidazolidin-1 -yl)acetamide;
N-(4-chlorophenyl)-2-(4,4-diethyl-2,5-dioxoimidazolidin-1 -yl)acetamide;
2- (4,4-diethyl-2,5-dioxoimidazolidin-1 -yl)-N-(4-fluorophenyl)acetamide;
N-(4-bromophenyl)-2-[4-methyl-2,5-dioxo-4-(2-phenylethyl)imidazolidin-1 - yl]acetamide;
N-(4-bromophenyl)-1 ,3,3a,4,7,7a-hexahydro-1 ,3-dioxo-4,7-methano-2H-isoindole-2- acetamide; and
N-(4-bromophenyl)-1 ,3,3a,4,7,7a-hexahydro-1 ,3-dioxo-2H-isoindole-2-acetamide.
PCT/US2014/020273 2013-03-06 2014-03-04 Use of agonists of formyl peptide receptor 2 for treating dermatological diseases WO2014138046A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
CA2899804A CA2899804A1 (en) 2013-03-06 2014-03-04 Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
CN201480011861.8A CN105007908B (en) 2013-03-06 2014-03-04 For the purposes for the activator for treating dermopathic formyl peptide receptor 2
KR1020217005968A KR20210024691A (en) 2013-03-06 2014-03-04 Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
BR112015021392-8A BR112015021392B1 (en) 2013-03-06 2014-03-04 USE OF FORMIL 2 PEPTIDE RECEPTOR AGONISTS TO TREAT DERMATOLOGICAL DISEASES
KR1020157024039A KR102223384B1 (en) 2013-03-06 2014-03-04 Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
BR122017004256A BR122017004256A2 (en) 2013-03-06 2014-03-04 use of formyl 2 peptide receptor agonists to treat dermatological diseases
RU2015134778A RU2696487C2 (en) 2013-03-06 2014-03-04 Using formylpeptide receptor 2 agonists for treating dermatologic diseases
EP14713302.9A EP2964214A1 (en) 2013-03-06 2014-03-04 Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
JP2015561540A JP6196328B2 (en) 2013-03-06 2014-03-04 Use of formyl peptide receptor 2 agonists to treat skin diseases
AU2014226001A AU2014226001B2 (en) 2013-03-06 2014-03-04 Use of agonists of Formyl peptide receptor 2 for treating dermatological diseases
HK16107753.4A HK1219661A1 (en) 2013-03-06 2016-07-05 Use of agonists of formyl peptide receptor for treating dermatological diseases
AU2019201538A AU2019201538B2 (en) 2013-03-06 2019-03-06 Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
AU2021203183A AU2021203183A1 (en) 2013-03-06 2021-05-18 Use of agonists of formyl peptide receptor 2 for treating dermatological diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361773778P 2013-03-06 2013-03-06
US61/773,778 2013-03-06

Publications (1)

Publication Number Publication Date
WO2014138046A1 true WO2014138046A1 (en) 2014-09-12

Family

ID=50389505

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/020273 WO2014138046A1 (en) 2013-03-06 2014-03-04 Use of agonists of formyl peptide receptor 2 for treating dermatological diseases

Country Status (13)

Country Link
US (5) US20140256685A1 (en)
EP (1) EP2964214A1 (en)
JP (4) JP6196328B2 (en)
KR (2) KR20210024691A (en)
CN (2) CN105007908B (en)
AR (1) AR095035A1 (en)
AU (3) AU2014226001B2 (en)
BR (2) BR112015021392B1 (en)
CA (3) CA2899804A1 (en)
HK (2) HK1219661A1 (en)
RU (1) RU2696487C2 (en)
TW (1) TW201446241A (en)
WO (1) WO2014138046A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9139524B2 (en) 2012-05-16 2015-09-22 Actelion Pharmaceuticals Ltd. Fluorinated bridged spiro[2.4]heptane derivatives as ALX receptor agonists
US9284288B2 (en) 2012-05-16 2016-03-15 Actelion Pharmaceuticals Ltd. 1-(p-tolyl) cyclopropyl substituted bridged spiro[2.4]heptane derivatives as ALX receptor agonists
US9533964B2 (en) 2013-07-18 2017-01-03 Actelion Pharmaceuticals Ltd. Piperazine substituted bridged spiro[2.4]heptane derivatives as ALX receptor agonists
US9663473B2 (en) 2013-08-09 2017-05-30 Actelion Pharmaceuticals Ltd. Benzimidazolyl-methyl urea derivatives as ALX receptor agonists
US9663457B2 (en) 2014-04-09 2017-05-30 Allergan, Inc. Carbamoyl hydrazine derivatives as formyl peptide modulators
US9676761B2 (en) 2013-06-25 2017-06-13 Actelion Pharmaceuticals, Ltd. Difluoroethyl-oxazole substituted bridged spiro[2.4]heptane derivatives as ALX receptor agonists
JP2018536687A (en) * 2015-12-10 2018-12-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Piperidinone formyl peptide receptor 2 and formyl peptide receptor 1 agonist
JP2019515901A (en) * 2016-04-12 2019-06-13 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ Phenyl urea derivatives as N-formyl peptide receptor modulators
JP2019517997A (en) * 2016-03-28 2019-06-27 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ Phenyl urea derivatives as N-formyl peptide receptor modulators

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012329098B2 (en) 2011-10-26 2017-08-03 Allergan, Inc. Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
CN104302630A (en) * 2012-04-16 2015-01-21 阿勒根公司 (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators
CN107312039B (en) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 A kind of preparation method of tenofovir prodrug
CA2899804A1 (en) * 2013-03-06 2014-09-12 Allergan, Inc. Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
US9428549B2 (en) * 2013-07-16 2016-08-30 Allegran, Inc. Derivatives of N-urea substituted amino acids as formyl peptide receptor modulators
WO2015116566A1 (en) * 2014-01-29 2015-08-06 Allergan, Inc. 2,5-dioxoimidazolidin-1-yl-3-urea derivatives as formyl peptide modulators
EP3145916B1 (en) 2014-05-21 2020-02-12 Allergan, Inc. Imidazole derivatives as formyl peptide receptor modulators
RU2768587C2 (en) * 2016-10-06 2022-03-24 Дайити Санкио Компани, Лимитед Urea derivative
GB2561540A (en) * 2017-03-13 2018-10-24 Nodthera Ltd Chemical compounds
ES2799098B2 (en) * 2019-06-10 2021-12-10 Univ Madrid Carlos Iii AGONIST APTAMEROS OF THE FPR2 RECEPTOR AND USES OF THEM

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63232846A (en) 1987-03-20 1988-09-28 Haruo Ogura Novel stationary phase carrier
WO2001014328A2 (en) * 1999-08-20 2001-03-01 Merck & Co., Inc. Substituted ureas as cell adhesion inhibitors
US20050137230A1 (en) 2000-12-16 2005-06-23 Dieter Dorsch Carboxamide derivatives
KR20090121832A (en) * 2008-05-23 2009-11-26 인제대학교 산학협력단 2-(2-hydroxybenzoyl)hydrazinecarboxamide derivatives or pharmaceutically acceptable salts thereof, preparation method thereof, and phrmaceutical composition for the immunosuppression containing the same as an active ingredient
US7820673B2 (en) 2003-12-17 2010-10-26 Takeda Pharmaceutical Company Limited Urea derivative, process for producing the same, and use
US20120142726A1 (en) * 2010-12-03 2012-06-07 Allergan, Inc. Pharmaceutical compositions comprising 3,4-dihydroisoquinolin-2(1h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
WO2013009543A1 (en) * 2011-07-11 2013-01-17 Allergan, Inc. Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (fprl-1) receptor modulators
WO2013070600A1 (en) * 2011-11-10 2013-05-16 Allergan, Inc. Aryl urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521210A (en) 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
DE10005275A1 (en) * 2000-02-07 2001-08-09 Bayer Ag Novel glycoconjugates
EP1162194A1 (en) 2000-06-06 2001-12-12 Aventis Pharma Deutschland GmbH Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use
US20060160856A1 (en) * 2002-09-05 2006-07-20 Dahl Bjarne H Diarylurea derivatives and their use as chloride channel blockers
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
WO2006065755A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists
WO2007076055A2 (en) * 2005-12-22 2007-07-05 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
AU2009314165B2 (en) * 2008-11-11 2014-05-15 Signum Biosciences, Inc. Isoprenyl compounds and methods thereof
KR20100101054A (en) * 2009-03-07 2010-09-16 주식회사 메디젠텍 Composition for treating or preventing nuclear export of gsk3- mediated disease including compound for inhibiting nuclear export of gsk3
EP2585054A1 (en) * 2010-06-24 2013-05-01 Allergan, Inc. Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
WO2012109544A1 (en) 2011-02-11 2012-08-16 Allergan, Inc. Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators
US8653299B2 (en) 2011-03-17 2014-02-18 Allergan, Inc. Dihydronaphthalene and naphthalene derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
WO2012174243A1 (en) 2011-06-17 2012-12-20 Allergan, Inc. D -serine for the treatment of visual system disorders
AU2012329098B2 (en) * 2011-10-26 2017-08-03 Allergan, Inc. Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
US8492556B2 (en) * 2011-11-10 2013-07-23 Allergan, Inc. 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
EP2814815A1 (en) 2012-02-16 2014-12-24 Allergan, Inc. Imidazolidine-2,4-dione derivatives as n-formyl peptide receptor 2 modulators
CN104302630A (en) * 2012-04-16 2015-01-21 阿勒根公司 (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators
CA2899804A1 (en) * 2013-03-06 2014-09-12 Allergan, Inc. Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
KR102290134B1 (en) * 2013-03-06 2021-08-17 알러간, 인코포레이티드 Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
US9428549B2 (en) * 2013-07-16 2016-08-30 Allegran, Inc. Derivatives of N-urea substituted amino acids as formyl peptide receptor modulators
WO2015042071A1 (en) 2013-09-19 2015-03-26 Allergan, Inc. Diphenyl urea derivatives as formyl peptide receptor modulators
RU2703725C1 (en) 2013-11-21 2019-10-22 Аллерган, Инк. Phenylcarbamate derivatives as formyl peptide receptor modulators
EP3145916B1 (en) * 2014-05-21 2020-02-12 Allergan, Inc. Imidazole derivatives as formyl peptide receptor modulators

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63232846A (en) 1987-03-20 1988-09-28 Haruo Ogura Novel stationary phase carrier
WO2001014328A2 (en) * 1999-08-20 2001-03-01 Merck & Co., Inc. Substituted ureas as cell adhesion inhibitors
US20050137230A1 (en) 2000-12-16 2005-06-23 Dieter Dorsch Carboxamide derivatives
US7820673B2 (en) 2003-12-17 2010-10-26 Takeda Pharmaceutical Company Limited Urea derivative, process for producing the same, and use
KR20090121832A (en) * 2008-05-23 2009-11-26 인제대학교 산학협력단 2-(2-hydroxybenzoyl)hydrazinecarboxamide derivatives or pharmaceutically acceptable salts thereof, preparation method thereof, and phrmaceutical composition for the immunosuppression containing the same as an active ingredient
US20120142726A1 (en) * 2010-12-03 2012-06-07 Allergan, Inc. Pharmaceutical compositions comprising 3,4-dihydroisoquinolin-2(1h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
WO2013009543A1 (en) * 2011-07-11 2013-01-17 Allergan, Inc. Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (fprl-1) receptor modulators
WO2013070600A1 (en) * 2011-11-10 2013-05-16 Allergan, Inc. Aryl urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
BIOCHIMICA ET BIOPHYSICA ACTA, NUCLEIC ACIDS AND PROTEIN SYNTHESIS, vol. 272, no. 4, 1972, pages 667 - 71
CHIANG N; SERHAN CN; DAHLEN, S; DRAZEN JM; HAY DWP; ROVATI E; SHIMIZU T; YOKOMIZO T; BRINK, C.: "The lipoxin receptor ALX: Potent ligand-specific and stereoselective actions in vivo", PHARMACOLOGICAL REVIEWS, vol. 58, 2006, pages 463 - 519
CHIANG N; SERHAN CN; DAHLEN, S; DRAZEN JM; HAY DWP; ROVATI E; SHIMIZU T; YOKOMIZO T; BRINK, C.: "The lipoxin receptor ALX: Potent ligand-specific and stereoselective actions in vivo.", PHARMACOLOGICAL REVIEWS, vol. 58, 2006, pages 463 - 519
CHROMATOGRAPHIA, vol. 23, no. 10, 1987, pages 727 - 30
DUFTON N; HANNON R; BRANCALEONE V; DALLI J; PATEL HB; GRAY M; D'AQUISTO F; BUCKINGHAM JC; PERRETTI M; FLOWER RJ.: "Anti-inflammatory role of the murine formyl-peptide receptor 2: Ligand-specific effects on leukocyte responses and experimental inflammation.", JOURNAL OF IMMUNOLOGY, vol. 184, 2010, pages 2611 - 2619
DUFTON N; PERRETTI M.: "Therapeutic anti-inflammatory potential of formyl peptide receptor agonists.", PHARAMCOLOGY & THERAPEUTICS, vol. 127, 2010, pages 175 - 188, XP027117295
GAVINS FNE; HUGHES EL; BUSS NAPS; HOLLOWAY PM; GETTING SJ; BUCKINGHAM JC.: "Leukocyte recruitment in the brain in sepsis: involvement of the annexin1 FPR2/ALX anti-inflammatory system.", FASEB, vol. 26, 2012, pages 1 - 13
JOURNAL OF CHROMATOGRAPHY, vol. 404, no. 1, 1987, pages 117 - 22
LEEDOM A; SULLIVAN AB; DONG B; LAU D; GRONERT K.: "Endogenous LXA4 circuits are determinants of pathological angiogenesis in response to chronic injury", AMERICAN JOURNAL OF PATHOLOGY, vol. 176, 2010, pages 74 - 84
LEONI G; ALAM A; NEUMANN PA; LAMBETH JD; CHENG G; MCCOY J; HILGARTH RS; KUNDU K; MURTHY N; KUSTERS D: "Annexin A1, formyl peptide receptor, and NOX1 orchestrate epithelial repair", JOURNAL OF CLINICAL INVESTIGATION., vol. 123, 2013, pages 443 - 54
MADERNA P; COTTELL DC; TOIVONEN T; DUFTON N; DALLI J; PERRETTI M; GODSON C.: "FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin-derived peptide-stimulated phagocytosis.", FASEB, vol. 24, 2010, pages 4240 - 4249, XP055022195, DOI: doi:10.1096/fj.10-159913
REVILLE K; CREAM JK; VIVERS S; DRANSFIELD , GODSON C.: "Lipoxin A4 redistributes Mysoin IIA and Cdc42 in macrophages: Implications for phagocytosis of apoptotic leukocytes.", JOURNAL OF IMMUNOLOGY, vol. 176, 2006, pages 1878 - 1888
SERHAN C.: "Resolution phase of inflammation: Novel endogenous anti-inflammatory and proresolving lipid mediators and pathways.", ANNUAL REVIEWS OF IMMUNOLOGY, vol. 25, 2007, pages 101 - 137
TAKANO T; FIORE S; MADDOX JF; BRADY HR; PETASIS NA; SERHAN CN.: "Asprin-triggered 15-epi-lipoxin A4 and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 185, 1997, pages 1693 - 1704, XP002141526, DOI: doi:10.1084/jem.185.9.1693
TSURUKI T ET AL: "Orally administered FPRL1 receptor agonist peptide MMK-1 inhibits etoposide-induced alopecia by a mechanism different from intraperitoneally administered MMK-1", PEPTIDES, ELSEVIER, AMSTERDAM, NL, vol. 27, no. 4, 1 April 2006 (2006-04-01), pages 820 - 825, XP027957734, ISSN: 0196-9781, [retrieved on 20060401] *
TSURUKI T; TAKAHATA K; YOSHIKAWA M.: "Mechanism of the protective effect of intraperitoneally administered agonists for formyl peptide receptors against chemotherapy-induced alopecia", BIOSCI BIOTECHNOLOGY BIOCHEMISTRY, vol. 71, 2007, pages 1198 - 202
YAMASAKI K; DI NARDO A; BARDAN A; MURAKAMI M; OHTAKE T; CODA A; DORSCHNER RA; BONNART C; DESCARGUES P; HOVNANIAN A: "Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea.", NATURE MEDICINE, vol. 13, 2007, pages 975 - 80, XP002616691, DOI: doi:10.1038/nm1616

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9284288B2 (en) 2012-05-16 2016-03-15 Actelion Pharmaceuticals Ltd. 1-(p-tolyl) cyclopropyl substituted bridged spiro[2.4]heptane derivatives as ALX receptor agonists
US9139524B2 (en) 2012-05-16 2015-09-22 Actelion Pharmaceuticals Ltd. Fluorinated bridged spiro[2.4]heptane derivatives as ALX receptor agonists
US9676761B2 (en) 2013-06-25 2017-06-13 Actelion Pharmaceuticals, Ltd. Difluoroethyl-oxazole substituted bridged spiro[2.4]heptane derivatives as ALX receptor agonists
US9533964B2 (en) 2013-07-18 2017-01-03 Actelion Pharmaceuticals Ltd. Piperazine substituted bridged spiro[2.4]heptane derivatives as ALX receptor agonists
US9663473B2 (en) 2013-08-09 2017-05-30 Actelion Pharmaceuticals Ltd. Benzimidazolyl-methyl urea derivatives as ALX receptor agonists
US9868700B2 (en) 2014-04-09 2018-01-16 Allergan, Inc. Carbamoyl hydrazine derivatives as formyl peptide modulators
US9663457B2 (en) 2014-04-09 2017-05-30 Allergan, Inc. Carbamoyl hydrazine derivatives as formyl peptide modulators
JP2018536687A (en) * 2015-12-10 2018-12-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Piperidinone formyl peptide receptor 2 and formyl peptide receptor 1 agonist
JP2019517997A (en) * 2016-03-28 2019-06-27 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ Phenyl urea derivatives as N-formyl peptide receptor modulators
US11117860B2 (en) 2016-03-28 2021-09-14 Allergan, Inc. Phenyl urea derivatives as n-formyl peptide receptor modulators
JP7032323B2 (en) 2016-03-28 2022-03-08 アラーガン、インコーポレイテッド Phenylurea derivative as N-formylmethionide receptor modulator
JP7032323B6 (en) 2016-03-28 2023-12-18 アラーガン、インコーポレイテッド Phenylurea derivatives as N-formyl peptide receptor modulators
JP2019515901A (en) * 2016-04-12 2019-06-13 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ Phenyl urea derivatives as N-formyl peptide receptor modulators
US11286234B2 (en) 2016-04-12 2022-03-29 Allergan, Inc. Phenyl urea derivatives as N-formyl peptide receptor modulators

Also Published As

Publication number Publication date
AU2014226001B2 (en) 2018-12-06
AU2014226001A1 (en) 2015-09-03
AU2019201538B2 (en) 2021-02-18
BR122017004256A2 (en) 2019-09-10
JP2016512194A (en) 2016-04-25
EP2964214A1 (en) 2016-01-13
TW201446241A (en) 2014-12-16
HK1219661A1 (en) 2017-04-13
BR112015021392A2 (en) 2017-07-18
HK1251185A1 (en) 2019-01-25
US20210000846A1 (en) 2021-01-07
CN105007908B (en) 2017-10-03
CN107714683A (en) 2018-02-23
RU2696487C2 (en) 2019-08-02
BR112015021392B1 (en) 2021-11-16
JP2019108391A (en) 2019-07-04
KR20210024691A (en) 2021-03-05
AR095035A1 (en) 2015-09-16
JP6496788B2 (en) 2019-04-03
CA3114347A1 (en) 2014-09-12
US10799518B2 (en) 2020-10-13
CN105007908A (en) 2015-10-28
CA3114477A1 (en) 2014-09-12
US20200246360A1 (en) 2020-08-06
US10434112B2 (en) 2019-10-08
JP6196328B2 (en) 2017-09-13
KR102223384B1 (en) 2021-03-05
JP6496787B2 (en) 2019-04-03
US20170216326A1 (en) 2017-08-03
US20210008085A1 (en) 2021-01-14
RU2015134778A (en) 2017-04-10
JP2017214417A (en) 2017-12-07
AU2021203183A1 (en) 2021-06-10
JP2017214418A (en) 2017-12-07
US20140256685A1 (en) 2014-09-11
CA2899804A1 (en) 2014-09-12
JP6672499B2 (en) 2020-03-25
AU2019201538A1 (en) 2019-03-28
KR20150123249A (en) 2015-11-03

Similar Documents

Publication Publication Date Title
JP6672499B2 (en) Use of formyl peptide receptor 2 agonist for treating skin diseases
US10899780B2 (en) Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14713302

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2899804

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2014713302

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 122017004256

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2014226001

Country of ref document: AU

Date of ref document: 20140304

Kind code of ref document: A

Ref document number: 20157024039

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2015561540

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2015134778

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015021392

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112015021392

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20150902